Clinical Translation of Nanomedicine

Chemical Reviews

Volumn 115, Issue 19, 2015, Pages 11147-11190

  Min, Yuanzeng ^a   Caster, Joseph M ^a   Eblan, Michael J ^a   Wang, Andrew Z ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS; LEAD COMPOUNDS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

CHEMORESISTANCE; CLINICAL TRANSLATION; COST EFFECTIVENESS ANALYSIS; FOOD AND DRUG ADMINISTRATION; INVESTIGATIONAL NEW DRUGS; NANOFORMULATION; SMALL MOLECULES; THERAPEUTIC EFFICACY;

TARGETED DRUG DELIVERY;

DRUG; LIPID; LIPOSOME; MICELLE; NANOPARTICLE; POLYMER; PROTEIN;

ANIMAL; CHEMISTRY; HUMAN; MICELLE; NANOMEDICINE; TRANSLATIONAL RESEARCH;

ANIMALS; HUMANS; LIPIDS; LIPOSOMES; MICELLES; NANOMEDICINE; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POLYMERS; PROTEINS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84942784694     PISSN: 00092665     EISSN: 15206890     Source Type: Journal    
DOI: 10.1021/acs.chemrev.5b00116     Document Type: Review

References (381)

1. Wagner, V.; Dullaart, A.; Bock, A. K.; Zweck, A. The Emerging Nanomedicine Landscape Nat. Biotechnol. 2006, 24, 1211-1217
2. Webster, T. J. Nanomedicine: whats in a definition? Int. J. Nanomed. 2006, 1, 115-116
3. Etheridge, M. L.; Campbell, S. A.; Erdman, A. G.; Haynes, C. L.; Wolf, S. M.; McCullough, J. The Big Picture on Nanomedicine: the state of investigational and approved nanomedicine products Nanomedicine 2013, 9, 1-14
4. Hay, M.; Thomas, D. W.; Craighead, J. L.; Economides, C.; Rosenthal, J. Clinical Development Success Rates for Investigational Drugs Nat. Biotechnol. 2014, 32, 40-51
5. Lipsky, M. S.; Sharp, L. K. From Idea to Market: the drug approval process J. Am. Board Fam. Med. 2001, 14, 362-367
6. Ivy, S. P.; Siu, L. L.; Garrett-Mayer, E.; Rubinstein, L. Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee Clin. Cancer Res. 2010, 16, 1726-1736
7. Le Tourneau, C.; Lee, J. J.; Siu, L. L. Dose Escalation Methods in Phase I Cancer Clinical Trials J. Natl. Cancer Inst. 2009, 101, 708-720
8. Seymour, L.; Ivy, S. P.; Sargent, D.; Spriggs, D.; Baker, L.; Rubinstein, L.; Ratain, M. J.; Le Blanc, M.; Stewart, D.; Crowley, J. et al. The Design of Phase II Clinical Trials Testing Cancer Therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee Clin. Cancer Res. 2010, 16, 1764-1769
9. Dolgin, E. First Breakthrough' Drugs Designated, but Dilution Worries Linger Nat. Med. 2013, 19, 116-117
10. Jarow, J. P.; Baxley, J. H. Medical Devices: US Medical Device Regulation Urol. Oncol. 2015, 33, 128-132
11. Deamer, D. W. From "Banghasomes" to Liposomes: A Memoir of Alec Bangham, 1921-2010 FASEB J. 2010, 24, 1308-1310
12. Sessa, G.; Weissmann, G. Phospholipid Spherules (Liposomes) as A Model for Biological Membranes J. Lipid Res. 1968, 9, 310-318
13. Gregoriadis, G.; Ryman, B. E. Liposomes as Carriers of Enzymes or Drugs: a New Approach to the Treatment of Storage Diseases Biochem. J. 1971, 124, 58P
14. Gregoriadis, G.; Leathwood, P. D.; Ryman, B. E. Enzyme Entrapment in Liposomes FEBS Lett. 1971, 14, 95-99
15. Allen, T. M.; Cullis, P. R. Liposomal Drug Delivery Systems: from Concept to Clinical Applications Adv. Drug Delivery Rev. 2013, 65, 36-48
16. Plautz, G. E.; Nabel, E. G.; Fox, B.; Yang, Z. Y.; Jaffe, M.; Gordon, D.; Chang, A.; Nabel, G. J. Direct Gene Transfer for the Understanding and Treatment of Human Disease Ann. N. Y. Acad. Sci. 1994, 716, 144-153
17. Gregoriadis, G. Drug Entrapment in Liposomes FEBS Lett. 1973, 36, 292-296
18. Gregoriadis, G.; Wills, E. J.; Swain, C. P.; Tavill, A. S. Drug-Carrier Potential of Liposomes in Cancer Chemotherapy Lancet 1974, 1, 1313-1316
19. Blum, R. H.; Carter, S. K. A New Anticancer Drug with Significant Clinical Activity Ann. Int. Med. 1974, 80, 249-259
20. Weiss, R. B. The Anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 1992, 19, 670-686
21. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 2004, 56, 185-229
22. Saltiel, E.; McGuire, W. Doxorubicin (adriamycin) cardiomyopathy West. J. Med. 1983, 139, 332-341
23. Lipshultz, S. E.; Karnik, R.; Sambatakos, P.; Franco, V. I.; Ross, S. W.; Miller, T. L. Anthracycline-Related cardiotoxicity in childhood cancer survivors Curr. Opin. Cardiol. 2014, 29, 103-112
24. Vejpongsa, P.; Yeh, E. T. Prevention of Anthracycline-Induced Cardiotoxicity: challenges and opportunities J. Am. Coll. Cardiol. 2014, 64, 938-945
25. Gabizon, A.; Peretz, T.; Sulkes, A.; Amselem, S.; Ben-Yosef, R.; Ben-Baruch, N.; Catane, R.; Biran, S.; Barenholz, Y. Systemic Administration of Doxorubicin-Containing Liposomes in Cancer Patients: a phase I study Eur. J. Cancer 1989, 25, 1795-1803
26. Barenholz, Y. Doxil(R)-the First FDA-Approved Nano-Drug: lessons learned J. Controlled Release 2012, 160, 117-134
27. Gabizon, A.; Chisin, R.; Amselem, S.; Druckmann, S.; Cohen, R.; Goren, D.; Fromer, I.; Peretz, T.; Sulkes, A.; Barenholz, Y. Pharmacokinetic and Imaging Studies in Patients Receiving a Formulation of Liposome-associated Adriamycin Br. J. Cancer 1991, 64, 1125-1132
28. Poste, G.; Bucana, C.; Raz, A.; Bugelski, P.; Kirsh, R.; Fidler, I. J. Analysis of the Fate of Systemically Administered Liposomes and Implications for Their Use in Drug Delivery Cancer Res. 1982, 42, 1412-1422
29. Rahman, A.; Treat, J.; Roh, J. K.; Potkul, L. A.; Alvord, W. G.; Forst, D.; Woolley, P. V. A Phase I Clinical Trial and Pharmacokinetic Evaluation of Liposome-Encapsulated Doxorubicin J. Clin. Oncol. 1990, 8, 1093-1100
30. Haran, G.; Cohen, R.; Bar, L. K.; Barenholz, Y. Transmembrane Ammonium Sulfate Gradients in Liposomes Produce Efficient and Stable Entrapment of Amphipathic Weak Bases Biochim. Biophys. Acta 1993, 1151, 201-215
31. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Polyethylene-glycol Coated Liposomes Cancer Res. 1994, 54, 987-992
32. Kaplan, L. D.; Wofsy, C. B.; Volberding, P. A. Treatment of Patients with Acquired Immunodeficiency Syndrome and Associated Manifestations JAMA, J. Am. Med. Assoc. 1987, 257, 1367-1374
33. Laubenstein, L. J.; Krigel, R. L.; Odajnyk, C. M.; Hymes, K. B.; Friedman-Kien, A.; Wernz, J. C.; Muggia, F. M. Treatment of Epidemic Kaposi's Sarcoma with Etoposide or A Combination of Doxorubicin, Bleomycin, and Vinblastine J. Clin. Oncol. 1984, 2, 1115-1120
34. James, N. D.; Coker, R. J.; Tomlinson, D.; Harris, J. R.; Gompels, M.; Pinching, A. J.; Stewart, J. S. Liposomal Doxorubicin (Doxil): An Effective New Treatment for Kaposi's Sarcoma in AIDS Clin. Oncol. 1994, 6, 294-296
35. Hengge, U. R.; Brockmeyer, N. H.; Baumann, M.; Reimann, G.; Goos, M. Liposomal Doxorubicin in AIDS-Related Kaposi's Sarcoma Lancet 1993, 342, 497
36. DOXIL Approved by FDA. AIDS Patient Care 1995, 9, 306.
37. Stewart, S.; Jablonowski, H.; Goebel, F. D.; Arasteh, K.; Spittle, M.; Rios, A.; Aboulafia, D.; Galleshaw, J.; Dezube, B. J. Randomized Comparative Trial of Pegylated Liposomal Doxorubicin versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma J. Clin. Oncol. 1998, 16, 683-691
38. Northfelt, D. W.; Dezube, B. J.; Thommes, J. A.; Miller, B. J.; Fischl, M. A.; Friedman-Kien, A.; Kaplan, L. D.; Du Mond, C.; Mamelok, R. D.; Henry, D. H. Pegylated-Liposomal Doxorubicin versus Doxorubicin, Bleomycin, and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma: Results of A Randomized Phase III Clinical Trial J. Clin. Oncol. 1998, 16, 2445-2451
39. Udhrain, A.; Skubitz, K. M.; Northfelt, D. W. Pegylated Liposomal Doxorubicin in The Treatment of AIDS-related Kaposi's Sarcoma Int. J. Nanomed. 2007, 2, 345-352
40. Martin-Carbonero, L.; Barrios, A.; Saballs, P.; Sirera, G.; Santos, J.; Palacios, R.; Valencia, M. E.; Alegre, M.; Podzamczer, D.; Gonzalez-Lahoz, J. Pegylated Liposomal Doxorubicin plus Highly Active Antiretroviral Therapy versus Highly Active Antiretroviral Therapy Alone in HIV Patients with Kaposi's Sarcoma AIDS 2004, 18, 1737-1740
41. Muggia, F. M.; Hainsworth, J. D.; Jeffers, S.; Miller, P.; Groshen, S.; Tan, M.; Roman, L.; Uziely, B.; Muderspach, L.; Garcia, A. et al. Phase II Study of Liposomal Doxorubicin in Refractory Ovarian Cancer: Antitumor Activity and Toxicity Modification by Liposomal Encapsulation J. Clin. Oncol. 1997, 15, 987-993
42. Gordon, A. N.; Granai, C. O.; Rose, P. G.; Hainsworth, J.; Lopez, A.; Weissman, C.; Rosales, R.; Sharpington, T. Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer J. Clin. Oncol. 2000, 18, 3093-3100
43. 2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the Peritoneum Gynecol. Oncol. 2000, 78, 369-372
44. Gordon, A. N.; Fleagle, J. T.; Guthrie, D.; Parkin, D. E.; Gore, M. E.; Lacave, A. J. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin versus Topotecan J. Clin. Oncol. 2001, 19, 3312-3322
45. Gordon, A. N.; Tonda, M.; Sun, S.; Rackoff, W. Long-Term Survival Advantage for Women Treated with Pegylated Liposomal Doxorubicin Compared with Topotecan in A Phase 3 Randomized Study of Recurrent and Refractory Epithelial Ovarian Cancer Gynecol. Oncol. 2004, 95, 1-8
46. Markman, M.; Moon, J.; Wilczynski, S.; Lopez, A. M.; Rowland, K. M., Jr.; Michelin, D. P.; Lanzotti, V. J.; Anderson, G. L.; Alberts, D. S. Single Agent Carboplatin versus Carboplatin plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer: Final Survival Results of A SWOG (S0200) Phase 3 Randomized Trial Gynecol. Oncol. 2010, 116, 323-325
47. Ning, Y. M.; He, K.; Dagher, R.; Sridhara, R.; Farrell, A. T.; Justice, R.; Pazdur, R. Liposomal Doxorubicin in Combination with Bortezomib for Relapsed or Refractory Multiple Myeloma Oncology (Williston Park) 2007, 21, 1503-1508
48. Orlowski, R. Z.; Nagler, A.; Sonneveld, P.; Blade, J.; Hajek, R.; Spencer, A.; San Miguel, J.; Robak, T.; Dmoszynska, A.; Horvath, N. et al. Randomized Phase III Study of Pegylated Liposomal Doxorubicin plus Bortezomib Compared with Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression J. Clin. Oncol. 2007, 25, 3892-3901
49. Lyseng-Williamson, K. A.; Duggan, S. T.; Keating, G. M. Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies BioDrugs 2013, 27, 533-540
50. O'Brien, M. E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D. G.; Tomczak, P.; Ackland, S. P. et al. Reduced Cardiotoxicity and Comparable Efficacy in A Phase III Trial of Pegylated Liposomal Doxorubicin HCl (CAELYX/Doxil) versus Conventional Doxorubicin for First-Line Treatment of Metastatic Breast Cancer Ann. Oncol. 2004, 15, 440-449
51. Keller, A. M.; Mennel, R. G.; Georgoulias, V. A.; Nabholtz, J. M.; Erazo, A.; Lluch, A.; Vogel, C. L.; Kaufmann, M.; von Minckwitz, G.; Henderson, I. C. et al. Randomized Phase III Trial of Pegylated Liposomal Doxorubicin versus Vinorelbine or Mitomycin C plus Vinblastine in Women with Taxane-Refractory Advanced Breast Cancer J. Clin. Oncol. 2004, 22, 3893-3901
52. Burgess, P.; Hutt, P. B.; Farokhzad, O. C.; Langer, R.; Minick, S.; Zale, S. On Firm Ground: IP Protection of Therapeutic Nanoparticles Nat. Biotechnol. 2010, 28, 1267-1270
53. Hong, R. L.; Tseng, Y. L. Phase I and Pharmacokinetic Study of A Stable, Polyethylene-glycolated Liposomal Doxorubicin in Patients with Solid Tumors: the Relation Between Pharmacokinetic Property and Toxicity Cancer 2001, 91, 1826-1833
54. Chang, H. I.; Yeh, M. K. Clinical Development of Liposome-based Drugs: Formulation, Characterization, and Therapeutic Efficacy Int. J. Nanomed. 2012, 7, 49-60
55. Chan, S.; Davidson, N.; Juozaityte, E.; Erdkamp, F.; Pluzanska, A.; Azarnia, N.; Lee, L. W. Phase III Trial of Liposomal Doxorubicin and Cyclophosphamide Compared with Epirubicin and Cyclophosphamide as First-Line Therapy for Metastatic Breast Cancer Ann. Oncol. 2004, 15, 1527-1534
56. Harris, L.; Batist, G.; Belt, R.; Rovira, D.; Navari, R.; Azarnia, N.; Welles, L.; Winer, E. Liposome-Encapsulated Doxorubicin Compared with Conventional Doxorubicin in A Randomized Multicenter Trial as First-Line Therapy of Metastatic Breast Carcinoma Cancer 2002, 94, 25-36
57. Hossann, M.; Wang, T.; Wiggenhorn, M.; Schmidt, R.; Zengerle, A.; Winter, G.; Eibl, H.; Peller, M.; Reiser, M.; Issels, R. D.; Lindner, L. H. Size of Thermosensitive Liposomes Influences Content Release J. Controlled Release 2010, 147, 436-443
58. Venditti, J. M.; Abbott, B. J.; Dimarco, A.; Goldin, A. Effectiveness of Daunomycin (NSC-82151) Against Experimental Tumors Cancer Chemother. Rep. 1966, 50, 659-665
59. Guaglianone, P.; Chan, K.; DelaFlor-Weiss, E.; Hanisch, R.; Jeffers, S.; Sharma, D.; Muggia, F. Phase I and Pharmacologic Study of Liposomal Daunorubicin (DaunoXome) Invest. New Drugs 1994, 12, 103-110
60. Gill, P. S.; Espina, B. M.; Muggia, F.; Cabriales, S.; Tulpule, A.; Esplin, J. A.; Liebman, H. A.; Forssen, E.; Ross, M. E.; Levine, A. M. Phase I/II Clinical and Pharmacokinetic Evaluation of Liposomal Daunorubicin J. Clin. Oncol. 1995, 13, 996-1003
61. Gill, P. S.; Wernz, J.; Scadden, D. T.; Cohen, P.; Mukwaya, G. M.; von Roenn, J. H.; Jacobs, M.; Kempin, S.; Silverberg, I.; Gonzales, G. et al. Randomized Phase III Trial of Liposomal Daunorubicin versus Doxorubicin, Bleomycin, and Vincristine in AIDS-Related Kaposi's Sarcoma J. Clin. Oncol. 1996, 14, 2353-2364
62. Kaposis Sarcoma: DaunoXome Approved. AIDS Treatment News 1996, 3-4.
63. Baker, W. J.; Royer, G. L., Jr.; Weiss, R. B. Cytarabine and Neurologic Toxicity J. Clin. Oncol. 1991, 9, 679-693
64. Kim, S.; Turker, M. S.; Chi, E. Y.; Sela, S.; Martin, G. M. Preparation of Multivesicular Liposomes Biochim. Biophys. Acta 1983, 728, 339-348
65. Angst, M. S.; Drover, D. R. Pharmacology of Drugs Formulated with DepoFoam: A Sustained Release Drug Delivery System for Parenteral Administration Using Multivesicular Liposome Technology Clin. Pharmacokinet. 2006, 45, 1153-1176
66. Kim, S.; Khatibi, S.; Howell, S. B.; McCully, C.; Balis, F. M.; Poplack, D. G. Prolongation of Drug Exposure in Cerebrospinal Fluid by Encapsulation into DepoFoam Cancer Res. 1993, 53, 1596-1598
67. Chamberlain, M. C.; Khatibi, S.; Kim, J. C.; Howell, S. B.; Chatelut, E.; Kim, S. Treatment of Leptomeningeal Metastasis with Intraventricular Administration of Depot Cytarabine (DTC 101). A Phase I Study Arch. Neurol. 1993, 50, 261-264
68. Glantz, M. J.; LaFollette, S.; Jaeckle, K. A.; Shapiro, W.; Swinnen, L.; Rozental, J. R.; Phuphanich, S.; Rogers, L. R.; Gutheil, J. C.; Batchelor, T. et al. Randomized Trial of A Slow-Release versus A Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis J. Clin. Oncol. 1999, 17, 3110-3116
69. Tardi, P.; Johnstone, S.; Harasyrn, N.; Xie, S. W.; Harasyrn, T.; Zisman, N.; Harvie, P.; Bermudes, D.; Mayer, L. In Vivo Maintenance of Synergistic Cytarabine: Daunorubicin Ratios Greatly Enhances Therapeutic Efficacy Leuk. Res. 2009, 33, 129-139
70. Lim, W. S.; Tardi, P. G.; Dos Santos, N.; Xie, X. W.; Fan, M. N.; Liboiron, B. D.; Huang, X. P.; Harasym, T. O.; Bermudes, D.; Mayer, L. D. Leukemia-selective Uptake and Cytotoxicity of CPX-351, a Synergistic Fixed-ratio Cytarabine: Daunorubicin Formulation, in Bone Marrow Xenografts Leuk. Res. 2010, 34, 1214-1223
71. Carol, H.; Fan, M. M. Y.; Harasym, T. O.; Boehm, I.; Mayer, L. D.; Houghton, P.; Smith, M. A.; Lock, R. B. Efficacy of CPX-351, (Cytarabine:Daunorubicin) Liposome Injection, Against Acute Lymphoblastic Leukemia (ALL) Xenograft Models of the Pediatric Preclinical Testing Program Pediatr. Blood Cancer 2015, 62, 65-71
72. Gergis, U.; Roboz, G.; Shore, T.; Ritchie, E.; Mayer, S.; Wissa, U.; McKenna, M.; Christos, P.; Pearse, R.; Mark, T. et al. A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia Biol. Blood Marrow Transplant. 2013, 19, 1040-1045
73. Lancet, J. E.; Cortes, J. E.; Hogge, D. E.; Tallman, M. S.; Kovacsovics, T. J.; Damon, L. E.; Komrokji, R.; Solomon, S. R.; Kolitz, J. E.; Cooper, M. et al. Phase 2 Trial of CPX-351, a Fixed 5:1 Molar Ratio of Cytarabine/Daunorubicin, vs Cytarabine/Daunorubicin in Older Adults with Untreated AML Blood 2014, 123, 3239-3246
74. Cortes, J. E.; Goldberg, S. L.; Feldman, E. J.; Rizzeri, D. A.; Hogge, D. E.; Larson, M.; Pigneux, A.; Recher, C.; Schiller, G.; Warzocha, K. et al. Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine: daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML Cancer 2015, 121, 234-242
75. Harrison, T. S.; Lyseng-Williamson, K. A. Vincristine Sulfate Liposome Injection: A Guide to Its Use in Refractory or Relapsed Acute Lymphoblastic Leukemia BioDrugs 2013, 27, 69-74
76. Silverman, J. A.; Deitcher, S. R. Marqibo (Vincristine Sulfate Liposome Injection) Improves the Pharmacokinetics and Pharmacodynamics of Vincristine Cancer Chemother. Pharmacol. 2013, 71, 555-564
77. OBrien, S.; Schiller, G.; Lister, J.; Damon, L.; Goldberg, S.; Aulitzky, W.; Ben-Yehuda, D.; Stock, W.; Coutre, S.; Douer, D. et al. High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia J. Clin. Oncol. 2013, 31, 676-683
78. Rodriguez, M. A.; Pytlik, R.; Kozak, T.; Chhanabhai, M.; Gascoyne, R.; Lu, B.; Deitcher, S. R.; Winter, J. N. Vincristine Sulfate Liposomes Injection (Marqibo) in Heavily Pretreated Patients with Refractory Aggressive Non-Hodgkin Lymphoma: Report of the Pivotal Phase 2 Study Cancer 2009, 115, 3475-3482
79. Kelland, L. The Resurgence of Platinum-Based Cancer Chemotherapy Nat. Rev. Cancer 2007, 7, 573-584
80. Amptoulach, S.; Tsavaris, N. Neurotoxicity Caused by the Treatment with Platinum Analogues Chemother. Res. Pract. 2011, 2011, 5
81. Barabas, K.; Milner, R.; Lurie, D.; Adin, C. Cisplatin: A Review of Toxicities and Therapeutic Applications Vet. Comp. Oncol. 2008, 6, 1-18
82. Liu, D.; He, C.; Wang, A. Z.; Lin, W. Application of Liposomal Technologies for Delivery of Platinum Analogs in Oncology Int. J. Nanomed. 2013, 8, 3309-3319
83. Stathopoulos, G. P. Liposomal Cisplatin: A New Cisplatin Formulation Anti-Cancer Drugs 2010, 21, 732-736
84. Seetharamu, N.; Kim, E.; Hochster, H.; Martin, F.; Muggia, F. Phase II Study of Liposomal Cisplatin (SPI-77) in Platinum-Sensitive Recurrences of Ovarian Cancer Anti-Cancer Res. 2010, 30, 541-545
85. Infante, J. R.; Keedy, V. L.; Jones, S. F.; Zamboni, W. C.; Chan, E.; Bendell, J. C.; Lee, W.; Wu, H.; Ikeda, S.; Kodaira, H. et al. Phase I and Pharmacokinetic Study of IHL-305 (PEGylated Liposomal Irinotecan) in Patients with Advanced Solid Tumors Cancer Chemother. Pharmacol. 2012, 70, 699-705
86. Ko, A. H.; Tempero, M. A.; Shan, Y. S.; Su, W. C.; Lin, Y. L.; Dito, E.; Ong, A.; Wang, Y. W.; Yeh, C. G.; Chen, L. T. A Multinational Phase 2 Study of Nanoliposomal Irinotecan Sucrosofate (PEP02, MM-398) for Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer Br. J. Cancer 2013, 109, 920-925
87. Fetterly, G. J.; Grasela, T. H.; Sherman, J. W.; Dul, J. L.; Grahn, A.; Lecomte, D.; Fiedler-Kelly, J.; Damjanov, N.; Fishman, M.; Kane, M. P. et al. Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia During Phase I Development of Liposome-Entrapped Paclitaxel Clin. Cancer Res. 2008, 14, 5856-5863
88. Bayraktar, S.; Bayraktar, U. D.; Rocha-Lima, C. M. Recent Developments in Palliative Chemotherapy for Locally Advanced and Metastatic Pancreas Cancer World J. Gastroenterol. 2010, 16, 673-682
89. A Phase I Study of Liposomal-Encapsulated Docetaxel (LE-DT) in Patients with Advanced Solid Tumor Malignancies. Cancer Chemother. Pharmacol. 2013, 71, 627-633.
90. Gabizon, A.; Amitay, Y.; Tzemach, D.; Gorin, J.; Shmeeda, H.; Zalipsky, S. Therapeutic Efficacy of A Lipid-Based Prodrug of Mitomycin C in Pegylated Liposomes: Studies with Human Gastro-Entero-Pancreatic Ectopic Tumor Models J. Controlled Release 2012, 160, 245-253
91. Gabizon, A. A.; Tzemach, D.; Horowitz, A. T.; Shmeeda, H.; Yeh, J.; Zalipsky, S. Reduced Toxicity and Superior Therapeutic Activity of A Mitomycin C Lipid-Based Prodrug Incorporated in Pegylated Liposomes Clin. Cancer Res. 2006, 12, 1913-1920
92. Hamill, R. J. Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity Drugs 2013, 73, 919-934
93. Gates, C.; Pinney, R. J. Amphotericin B and Iits Delivery by Liposomal and Lipid Formulations J. Clin. Pharm. Ther. 1993, 18, 147-153
94. Hiemenz, J. W.; Walsh, T. J. Lipid Formulations of Amphotericin B: Recent Progress and Future Directions Clin. Infect. Dis. 1996, 22, S133-144
95. Mehta, R. T.; Hopfer, R. L.; McQueen, T.; Juliano, R. L.; Lopez-Berestein, G. Toxicity and Therapeutic Effects in Mice of Liposome-Encapsulated Nystatin for Systemic Fungal Infections Antimicrob. Agents Chemother. 1987, 31, 1901-1903
96. Mehta, R. T.; Hopfer, R. L.; Gunner, L. A.; Juliano, R. L.; Lopez-Berestein, G. Formulation, Toxicity, and Antifungal Activity in vitro of Liposome-Encapsulated Nystatin as Therapeutic Agent for Systemic Candidiasis Antimicrob. Agents Chemother. 1987, 31, 1897-1900
97. Mehta, R. T.; Lopez-Berestein, G.; Hopfer, R. L.; Mehta, K.; White, R. A.; Juliano, R. L. Prophylaxis of Murine Candidiasis via Application of Liposome-Encapsulated Amphotericin B and A Muramyl Dipeptide Analog, Alone and in Combination Antimicrob. Agents Chemother. 1985, 28, 511-513
98. Mehta, R. T.; Mehta, K.; Lopez-Berestein, G.; Juliano, R. L. Effect of Liposomal Amphotericin B on Murine Macrophages and Lymphocytes Infect. Immun. 1985, 47, 429-433
99. Juliano, R. L.; Lopez-Berestein, G.; Hopfer, R.; Mehta, R.; Mehta, K.; Mills, K. Selective Toxicity and Enhanced Therapeutic Index of Liposomal Polyene Antibiotics in Systemic Fungal Infections Ann. N. Y. Acad. Sci. 1985, 446, 390-402
100. Lopez-Berestein, G.; Hopfer, R. L.; Mehta, R.; Mehta, K.; Hersh, E. M.; Juliano, R. L. Liposome-Encapsulated Amphotericin B for Treatment of Disseminated Candidiasis in Neutropenic Mice J. Infect. Dis. 1984, 150, 278-283
101. Mehta, R.; Lopez-Berestein, G.; Hopfer, R.; Mills, K.; Juliano, R. L. Liposomal Amphotericin B Is Toxic to Fungal Cells but not to Mammalian Cells Biochim. Biophys. Acta 1984, 770, 230-234
102. Lopez-Berestein, G.; Hopfer, R. L.; Mehta, R.; Mehta, K.; Hersh, E. M.; Juliano, R. L. Prophylaxis of Candida Albicans Infection in Neutropenic Mice with Liposome-Encapsulated Amphotericin B Antimicrob. Agents Chemother. 1984, 25, 366-367
103. Hopfer, R. L.; Mills, K.; Mehta, R.; Lopez-Berestein, G.; Fainstein, V.; Juliano, R. L. In vitro Antifungal Activities of Amphotericin B and Liposome-Encapsulated Amphotericin B Antimicrob. Agents Chemother. 1984, 25, 387-389
104. Mehta, K.; Juliano, R. L.; Lopez-Berestein, G. Stimulation of Macrophage Protease Secretion via Liposomal Delivery of Muramyl Dipeptide Derivatives to Intracellular Sites Immunology 1984, 51, 517-527
105. Lopez-Berestein, G.; Mehta, R.; Hopfer, R. L.; Mills, K.; Kasi, L.; Mehta, K.; Fainstein, V.; Luna, M.; Hersh, E. M.; Juliano, R. Treatment and Prophylaxis of Disseminated Infection due to Candida Albicans in Mice with Liposome-Encapsulated Amphotericin B J. Infect. Dis. 1983, 147, 939-945
106. Lopez-Berestein, G.; Mehta, K.; Mehta, R.; Juliano, R. L.; Hersh, E. M. The Activation of Human Monocytes by Liposome-Encapsulated Muramyl Dipeptide Analogues J. Immunol. 1983, 130, 1500-1502
107. Lopez-Berestein, G.; Mehta, R.; Hopfer, R.; Mehta, K.; Hersh, E. M.; Juliano, R. Effects of Sterols on the Therapeutic Efficacy of Liposomal Amphotericin B in Murine Candidiasis Cancer Drug Delivery 1983, 1, 37-42
108. Mehta, K.; Lopez-Berestein, G.; Hersh, E. M.; Juliano, R. L. Uptake of Liposomes and Liposome-Encapsulated Muramyl Dipeptide by Human Peripheral Blood Monocytes J. Leukocyte Biol. 1982, 32, 155-164
109. Lopez-Berestein, G.; Fainstein, V.; Hopfer, R.; Mehta, K.; Sullivan, M. P.; Keating, M.; Rosenblum, M. G.; Mehta, R.; Luna, M.; Hersh, E. M. et al. Liposomal Amphotericin B for the Treatment of Systemic Fungal Infections in Patients with Cancer: A Preliminary Study J. Infect. Dis. 1985, 151, 704-710
110. Lopez-Berestein, G.; Bodey, G. P.; Frankel, L. S.; Mehta, K. Treatment of Hepatosplenic Candidiasis with Liposomal-Amphotericin B J. Clin. Oncol. 1987, 5, 310-317
111. Kan, V. L.; Bennett, J. E.; Amantea, M. A.; Smolskis, M. C.; McManus, E.; Grasela, D. M.; Sherman, J. W. Comparative Safety, Tolerance, and Pharmacokinetics of Amphotericin B Lipid Complex and Amphotericin B Desoxycholate in Healthy Male Volunteers J. Infect. Dis. 1991, 164, 418-421
112. Kline, S.; Larsen, T. A.; Fieber, L.; Fishbach, R.; Greenwood, M.; Harris, R.; Kline, M. W.; Tennican, P. O.; Janoff, E. N. Limited Toxicity of Prolonged Therapy with High Doses of Amphotericin B Lipid Complex Clin. Infect. Dis. 1995, 21, 1154-1158
113. Sundar, S.; Murray, H. W. Cure of Antimony-Unresponsive Indian Visceral Leishmaniasis with Amphotericin B Lipid Complex J. Infect. Dis. 1996, 173, 762-765
114. Mehta, J.; Kelsey, S.; Chu, P.; Powles, R.; Hazel, D.; Riley, U.; Evans, C.; Newland, A.; Treleaven, J.; Singhal, S. Amphotericin B Lipid Complex (ABLC) for the Treatment of Confirmed or Presumed Fungal Infections in Immunocompromised Patients with Hematologic Malignancies Bone Marrow Transplant. 1997, 20, 39-43
115. Bowden, R. A.; Cays, M.; Gooley, T.; Mamelok, R. D.; van Burik, J. A. Phase I Study of Amphotericin B Colloidal Dispersion for the Treatment of Invasive Fungal Infections After Marrow Transplant J. Infect. Dis. 1996, 173, 1208-1215
116. Sanders, S. W.; Buchi, K. N.; Goddard, M. S.; Lang, J. K.; Tolman, K. G. Single-Dose Pharmacokinetics and Tolerance of A Cholesteryl Sulfate Complex of Amphotericin B Administered to Healthy Volunteers Antimicrob. Agents Chemother. 1991, 35, 1029-1034
117. White, M. H.; Bowden, R. A.; Sandler, E. S.; Graham, M. L.; Noskin, G. A.; Wingard, J. R.; Goldman, M.; van Burik, J. A.; McCabe, A.; Lin, J. S. et al. Randomized, Double-Blind Clinical Trial of Amphotericin B Colloidal Dispersion vs. Amphotericin B in the Empirical Treatment of Fever and Neutropenia Clin. Infect. Dis. 1998, 27, 296-302
118. White, M. H.; Anaissie, E. J.; Kusne, S.; Wingard, J. R.; Hiemenz, J. W.; Cantor, A.; Gurwith, M.; Du Mond, C.; Mamelok, R. D.; Bowden, R. A. Amphotericin B Colloidal Dispersion vs. Amphotericin B as Therapy for Invasive Aspergillosis Clin. Infect. Dis. 1997, 24, 635-642
119. Bowden, R.; Chandrasekar, P.; White, M. H.; Li, X.; Pietrelli, L.; Gurwith, M.; van Burik, J. A.; Laverdiere, M.; Safrin, S.; Wingard, J. R. A Double-Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients Clin. Infect. Dis. 2002, 35, 359-366
120. Heinemann, V.; Bosse, D.; Jehn, U.; Kahny, B.; Wachholz, K.; Debus, A.; Scholz, P.; Kolb, H. J.; Wilmanns, W. Pharmacokinetics of Liposomal Amphotericin B (Ambisome) in Critically Ill Patients Antimicrob. Agents Chemother. 1997, 41, 1275-1280
121. Meyerhoff, A. U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis Clin. Infect. Dis. 1999, 28, 42-48
122. Meunier, F.; Prentice, H. G.; Ringden, O. Liposomal Amphotericin B (AmBisome): Safety Data from A Phase II/III Clinical Trial J. Antimicrob. Chemother. 1991, 28, 83-91
123. Prentice, H. G.; Hann, I. M.; Herbrecht, R.; Aoun, M.; Kvaloy, S.; Catovsky, D.; Pinkerton, C. R.; Schey, S. A.; Jacobs, F.; Oakhill, A. et al. A Randomized Comparison of Liposomal versus Conventional Amphotericin B for the Treatment of Pyrexia of Unknown Origin in Neutropenic Patients Br. J. Haematol. 1997, 98, 711-718
124. Wingard, J. R.; White, M. H.; Anaissie, E.; Raffalli, J.; Goodman, J.; Arrieta, A. A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia. L Amph/ABLC Collaborative Study Group Clin. Infect. Dis. 2000, 31, 1155-1163
125. Johansen, H. K.; Gotzsche, P. C. Amphotericin B Lipid Soluble Formulations versus Amphotericin B in Cancer Patients with Neutropenia Cochrane Database Syst. Rev. 2014, 9, CD000969
126. Cunningham, R.; Humphreys, H. Once-Daily Gentamicin: Translating Theory into Practice Eur. J. Clin. Pharmacol. 1996, 50, 151-154
127. Nightingale, S. D.; Saletan, S. L.; Swenson, C. E.; Lawrence, A. J.; Watson, D. A.; Pilkiewicz, F. G.; Silverman, E. G.; Cal, S. X. Liposome-Encapsulated Gentamicin Treatment of Mycobacterium Avium-Mycobacterium Intracellulare Complex Bacteremia in AIDS Patients Antimicrob. Agents Chemother. 1993, 37, 1869-1872
128. Meers, P.; Neville, M.; Malinin, V.; Scotto, A. W.; Sardaryan, G.; Kurumunda, R.; Mackinson, C.; James, G.; Fisher, S.; Perkins, W. R. Biofilm Penetration, Triggered Release and in vivo Activity of Inhaled Liposomal Amikacin in Chronic Pseudomonas Aeruginosa Lung Infections J. Antimicrob. Chemother. 2008, 61, 859-868
129. Clancy, J. P.; Dupont, L.; Konstan, M. W.; Billings, J.; Fustik, S.; Goss, C. H.; Lymp, J.; Minic, P.; Quittner, A. L.; Rubenstein, R. C. et al. Phase II Studies of Nebulised Arikace in CF Patients with Pseudomonas Aeruginosa Infection Thorax 2013, 68, 818-825
130. Stegmann, T.; Morselt, H. W.; Booy, F. P.; van Breemen, J. F.; Scherphof, G.; Wilschut, J. Functional Reconstitution of Influenza virus Envelopes EMBO J. 1987, 6, 2651-2659
131. Kursteiner, O.; Moser, C.; Lazar, H.; Durrer, P. Inflexal V-the Influenza Vaccine with the Lowest Ovalbumin Content Vaccine 2006, 24, 6632-6635
132. Herzog, C.; Hartmann, K.; Kunzi, V.; Kursteiner, O.; Mischler, R.; Lazar, H.; Gluck, R. Eleven Years of Inflexal V-A Virosomal Adjuvanted Influenza Vaccine Vaccine 2009, 27, 4381-4387
133. Kanra, G.; Marchisio, P.; Feiterna-Sperling, C.; Gaedicke, G.; Lazar, H.; Durrer, P.; Kursteiner, O.; Herzog, C.; Kara, A.; Principi, N. Comparison of Immunogenicity and Tolerability of A Virosome-Adjuvanted and A Split Influenza Vaccine in Children Pediatr. Infect. Dis. J. 2004, 23, 300-306
134. Bovier, P. A. Epaxal: A Virosomal Vaccine to Prevent Hepatitis A Infection Expert Rev. Vaccines 2008, 7, 1141-1150
135. Bovier, P. A.; Bock, J.; Ebengo, T. F.; Frosner, G.; Glaus, J.; Herzog, C.; Loutan, L. Predicted 30-year Protection after Vaccination with An Aluminum-Free Virosomal Hepatitis A Vaccine J. Med. Virol. 2010, 82, 1629-1634
136. Hatz, C.; Beck, B.; Steffen, R.; Genton, B.; dAcremont, V.; Loutan, L.; Hartmann, K.; Herzog, C. Real-Life versus Package Insert: A Post-Marketing Study on Adverse-Event Rates of the Virosomal Hepatitis A Vaccine Epaxal(R) in Healthy Travellers Vaccine 2011, 29, 5000-5006
137. Gambling, D.; Hughes, T.; Martin, G.; Horton, W.; Manvelian, G. A Comparison of Depodur, A Novel, Single-Dose Extended-Release Epidural Morphine, with Standard Epidural Morphine for Pain Relief after Lower Abdominal Surgery Anesth. Analg. 2005, 100, 1065-1074
138. Viscusi, E. R.; Martin, G.; Hartrick, C. T.; Singla, N.; Manvelian, G. Forty-Eight Hours of Postoperative Pain Relief after Total Hip Arthroplasty with A Novel, Extended-Release Epidural Morphine Formulation Anesthesiology 2005, 102, 1014-1022
139. Peravali, R.; Brock, R.; Bright, E.; Mills, P.; Petty, D.; Alberts, J. Enhancing the Enhanced Recovery Program in Colorectal Surgery-Use of Extended-Release Epidural Morphine (DepoDur) Ann. Coloproctol. 2014, 30, 186-191
140. Gorfine, S. R.; Onel, E.; Patou, G.; Krivokapic, Z. V. Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Dis. Colon Rectum 2011, 54, 1552-1559
141. Marcet, J. E.; Nfonsam, V. N.; Larach, S. An Extended Pain Relief Trial Utilizing the Infiltration of A Long-Acting Multivesicular Liposome Formulation of bupivacaine, EXPAREL (IMPROVE): A Phase IV Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal J. Pain Res. 2013, 6, 549-555
142. Agosta, E.; Lazzeri, S.; Orlandi, P.; Figus, M.; Fioravanti, A.; Di Desidero, T.; Sartini, M. S.; Nardi, M.; Danesi, R.; Bocci, G. Pharmacogenetics of Antiangiogenic and Antineovascular Therapies of Age-Related Macular Degeneration Pharmacogenomics 2012, 13, 1037-1053
143. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: One-Year Results of 2 Randomized Clinical Trials-TAP Report. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Arch. Ophthalmol. 1999, 117, 1329-1345.
144. Lim, J. I.; Glassman, A. R.; Aiello, L. P.; Chakravarthy, U.; Flaxel, C. J.; Spaide, R. F. Collaborative Retrospective Macula Society Study of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Ophthalmology 2014, 121, 1073-1078
145. Zhao, M.; Zhang, F.; Chen, Y.; Dai, H.; Qu, J.; Dong, C.; Kang, X.; Liu, Y.; Yang, L.; Li, Y. et al. A 50% vs 30% Dose of Verteporfin (Photodynamic Therapy) for Acute Central Serous Chorioretinopathy: One-Year Results of a Randomized Clinical Trial JAMA Ophthalmol. 2015, 133, 333-340
146. Huggett, M. T.; Jermyn, M.; Gillams, A.; Illing, R.; Mosse, S.; Novelli, M.; Kent, E.; Bown, S. G.; Hasan, T.; Pogue, B. W. et al. Phase I/II Study of Verteporfin Photodynamic Therapy in Locally Advanced Pancreatic Cancer Br. J. Cancer 2014, 110, 1698-1704
147. Balazs, D. A.; Godbey, W. Liposomes for Use in Gene Delivery J. Drug Delivery 2011, 2011, 326497
148. Hortobagyi, G. N.; Ueno, N. T.; Xia, W.; Zhang, S.; Wolf, J. K.; Putnam, J. B.; Weiden, P. L.; Willey, J. S.; Carey, M.; Branham, D. L. et al. Cationic Liposome-Mediated E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial J. Clin. Oncol. 2001, 19, 3422-3433
149. Yoo, G. H.; Hung, M. C.; Lopez-Berestein, G.; LaFollette, S.; Ensley, J. F.; Carey, M.; Batson, E.; Reynolds, T. C.; Murray, J. L. Phase I Trial of Intratumoral Liposome E1A Gene Therapy in Patients with Recurrent Breast and Head and Neck Cancer Clin. Cancer Res. 2001, 7, 1237-1245
150. Senzer, N.; Nemunaitis, J.; Nemunaitis, D.; Bedell, C.; Edelman, G.; Barve, M.; Nunan, R.; Pirollo, K. F.; Rait, A.; Chang, E. H. Phase I Study of a Systemically Delivered P53 Nanoparticle in Advanced Solid Tumors Mol. Ther. 2013, 21, 1096-1103
151. Dritschilo, A.; Huang, C. H.; Rudin, C. M.; Marshall, J.; Collins, B.; Dul, J. L.; Zhang, C.; Kumar, D.; Gokhale, P. C.; Ahmad, A. et al. Phase I Study of Liposome-Encapsulated C-Raf Antisense Oligodeoxyribonucleotide Infusion in Combination with Radiation Therapy in Patients with Advanced Malignancies Clin. Cancer Res. 2006, 12, 1251-1259
152. Resnier, P.; Montier, T.; Mathieu, V.; Benoit, J. P.; Passirani, C. A Review of the Current Status of siRNA Nanomedicines in the Treatment of Cancer Biomaterials 2013, 34, 6429-6443
153. Coelho, T.; Adams, D.; Silva, A.; Lozeron, P.; Hawkins, P. N.; Mant, T.; Perez, J.; Chiesa, J.; Warrington, S.; Tranter, E. et al. Safety and Efficacy of Rnai Therapy for Transthyretin Amyloidosis N. Engl. J. Med. 2013, 369, 819-829
154. Kanasty, R.; Dorkin, J. R.; Vegas, A.; Anderson, D. Delivery Materials for siRNA Therapeutics Nat. Mater. 2013, 12, 967-977
155. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant Antitumor Agents. VI. The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from Taxus Brevifolia J. Am. Chem. Soc. 1971, 93, 2325-2327
156. Rowinsky, E. K.; Cazenave, L. A.; Donehower, R. C. Taxol: A Novel Investigational Antimicrotubule Agent J. Natl. Cancer Inst. 1990, 82, 1247-1259
157. Adams, J. D.; Flora, K. P.; Goldspiel, B. R.; Wilson, J. W.; Arbuck, S. G.; Finley, R. Taxol: A History of Pharmaceutical Development and Current Pharmaceutical Concerns J. Natl. Cancer Inst. Monogr. 1993, 141-147
158. Rowinsky, E. K.; Donehower, R. C. Paclitaxel (Taxol) N. Engl. J. Med. 1995, 332, 1004-1014
159. Dye, D.; Watkins, J. Suspected Anaphylactic Reaction to Cremophor EL BMJ 1980, 280, 1353
160. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The Drawbacks and Advantages of Vehicle Selection for Drug Formulation Eur. J. Cancer 2001, 37, 1590-1598
161. Weiss, R. B.; Donehower, R. C.; Wiernik, P. H.; Ohnuma, T.; Gralla, R. J.; Trump, D. L.; Baker, J. R., Jr.; Van Echo, D. A.; Von Hoff, D. D.; Leyland-Jones, B. Hypersensitivity Reactions from Taxol J. Clin. Oncol. 1990, 8, 1263-1268
162. ten Tije, A. J.; Verweij, J.; Loos, W. J.; Sparreboom, A. Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy Clin. Pharmacokinet. 2003, 42, 665-685
163. Winer, E. P.; Berry, D. A.; Woolf, S.; Duggan, D.; Kornblith, A.; Harris, L. N.; Michaelson, R. A.; Kirshner, J. A.; Fleming, G. F.; Perry, M. C. et al. Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients with Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342 J. Clin. Oncol. 2004, 22, 2061-2068
164. Sparreboom, A.; van Zuylen, L.; Brouwer, E.; Loos, W. J.; de Bruijn, P.; Gelderblom, H.; Pillay, M.; Nooter, K.; Stoter, G.; Verweij, J. Cremophor EL-Mediated Alteration of Paclitaxel Distribution in Human Blood: Clinical Pharmacokinetic Implications Cancer Res. 1999, 59, 1454-1457
165. Brouwer, E.; Verweij, J.; De Bruijn, P.; Loos, W. J.; Pillay, M.; Buijs, D.; Sparreboom, A. Measurement of Fraction Unbound Paclitaxel in Human Plasma Drug Metab. Dispos. 2000, 28, 1141-1145
166. Ibrahim, N. K.; Desai, N.; Legha, S.; Soon-Shiong, P.; Theriault, R. L.; Rivera, E.; Esmaeli, B.; Ring, S. E.; Bedikian, A.; Hortobagyi, G. N. et al. A. Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-Free, Protein-Stabilized, Nanoparticle Formulation of Paclitaxel Clin. Cancer Res. 2002, 8, 1038-1044
167. Nyman, D. W.; Campbell, K. J.; Hersh, E.; Long, K.; Richardson, K.; Trieu, V.; Desai, N.; Hawkins, M. J.; Von Hoff, D. D. Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients with Advanced Nonhematologic Malignancies J. Clin. Oncol. 2005, 23, 7785-7793
168. Desai, N.; Trieu, V.; Yao, Z.; Louie, L.; Ci, S.; Yang, A.; Tao, C.; De, T.; Beals, B.; Dykes, D. et al. Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel Clin. Cancer Res. 2006, 12, 1317-1324
169. Ibrahim, N. K.; Samuels, B.; Page, R.; Doval, D.; Patel, K. M.; Rao, S. C.; Nair, M. K.; Bhar, P.; Desai, N.; Hortobagyi, G. N. Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women with Metastatic Breast Cancer J. Clin. Oncol. 2005, 23, 6019-6026
170. Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; OShaughnessy, J. Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared with Polyethylated Castor Oil-Based Paclitaxel in Women with Breast Cancer J. Clin. Oncol. 2005, 23, 7794-7803
171. Jett, J. R.; Schild, S. E.; Keith, R. L.; Kesler, K. A. American College of Chest, P. Treatment of Non-Small Cell Lung Cancer, Stage IIIb: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest 2007, 132, 266S-276S
172. Kelly, K.; Crowley, J.; Bunn, P. A., Jr.; Presant, C. A.; Grevstad, P. K.; Moinpour, C. M.; Ramsey, S. D.; Wozniak, A. J.; Weiss, G. R.; Moore, D. F. et al. Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer: A Southwest Oncology Group Trial J. Clin. Oncol. 2001, 19, 3210-3218
173. Green, M. R.; Manikhas, G. M.; Orlov, S.; Afanasyev, B.; Makhson, A. M.; Bhar, P.; Hawkins, M. J. Abraxane, a Novel Cremophor-Free, Albumin-Bound Particle Form of Paclitaxel for the Treatment of Advanced Non-Small-Cell Lung Cancer Ann. Oncol. 2006, 17, 1263-1268
174. Ranson, M.; Davidson, N.; Nicolson, M.; Falk, S.; Carmichael, J.; Lopez, P.; Anderson, H.; Gustafson, N.; Jeynes, A.; Gallant, G. et al. Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients with Advanced Non-Small-Cell Lung Cancer J. Natl. Cancer Inst. 2000, 92, 1074-1080
175. Rizvi, N. A.; Riely, G. J.; Azzoli, C. G.; Miller, V. A.; Ng, K. K.; Fiore, J.; Chia, G.; Brower, M.; Heelan, R.; Hawkins, M. J. et al. Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel as Initial Chemotherapy in Patients with Stage IV Non-Small-Cell Lung Cancer J. Clin. Oncol. 2008, 26, 639-643
176. Socinski, M. A.; Manikhas, G. M.; Stroyakovsky, D. L.; Makhson, A. N.; Cheporov, S. V.; Orlov, S. V.; Yablonsky, P. K.; Bhar, P.; Iglesias, J. A Dose Finding Study of Weekly and Every-3-Week Nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer J. Thorac. Oncol. 2010, 5, 852-861
177. Socinski, M. A.; Bondarenko, I.; Karaseva, N. A.; Makhson, A. M.; Vynnychenko, I.; Okamoto, I.; Hon, J. K.; Hirsh, V.; Bhar, P.; Zhang, H. et al. Weekly Nab-Paclitaxel in Combination with Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial J. Clin. Oncol. 2012, 30, 2055-2062
178. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A. et al. Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 2007, 25, 1960-1966
179. Heinemann, V.; Boeck, S.; Hinke, A.; Labianca, R.; Louvet, C. Meta-Analysis of Randomized Trials: Evaluation of Benefit from Gemcitabine-Based Combination Chemotherapy Applied in Advanced Pancreatic Cancer BMC Cancer 2008, 8, 82
180. Louvet, C.; Labianca, R.; Hammel, P.; Lledo, G.; Zampino, M. G.; Andre, T.; Zaniboni, A.; Ducreux, M.; Aitini, E.; Taieb, J. et al. Gemcitabine in Combination with Oxaliplatin Compared with Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a Gercor and Giscad Phase III Trial J. Clin. Oncol. 2005, 23, 3509-3516
181. Heinemann, V.; Quietzsch, D.; Gieseler, F.; Gonnermann, M.; Schonekas, H.; Rost, A.; Neuhaus, H.; Haag, C.; Clemens, M.; Heinrich, B. et al. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared with Gemcitabine Alone in Advanced Pancreatic Cancer J. Clin. Oncol. 2006, 24, 3946-3952
182. Colucci, G.; Giuliani, F.; Gebbia, V.; Biglietto, M.; Rabitti, P.; Uomo, G.; Cigolari, S.; Testa, A.; Maiello, E.; Lopez, M. Gemcitabine Alone or with Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Prospective, Randomized Phase III Study of the Gruppo Oncologia Dellitalia Meridionale Cancer 2002, 94, 902-910
183. Von Hoff, D. D.; Ramanathan, R. K.; Borad, M. J.; Laheru, D. A.; Smith, L. S.; Wood, T. E.; Korn, R. L.; Desai, N.; Trieu, V.; Iglesias, J. L. et al. Gemcitabine Plus Nab-Paclitaxel Is an Active Regimen in Patients with Advanced Pancreatic Cancer: A Phase I/II Trial J. Clin. Oncol. 2011, 29, 4548-4554
184. Von Hoff, D. D.; Ervin, T.; Arena, F. P.; Chiorean, E. G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S. A.; Ma, W. W.; Saleh, M. N. et al. Increased Survival in Pancreatic Cancer with Nab-Paclitaxel Plus Gemcitabine N. Engl. J. Med. 2013, 369, 1691-1703
185. Sun, S.; Tang, L.; Zhang, J.; Lv, F.; Wang, Z.; Wang, L.; Zhang, Q.; Zheng, C.; Qiu, L.; Jia, Z. et al. Cisplatin Improves Antitumor Activity of Weekly Nab-paclitaxel in Patients with Metastatic Breast Cancer Int. J. Nanomed. 2014, 9, 1443-1452
186. Seidman, A. D.; Conlin, A. K.; Bach, A.; Moynahan, M. E.; Lake, D.; Forero, A.; Wright, G. S.; Hackney, M. H.; Clawson, A.; Norton, L. et al. Randomized Phase II Trial of Weekly Vs. Every 2 Weeks Vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel with Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer Clin. Breast Cancer 2013, 13, 239-246
187. Roy, V.; LaPlant, B. R.; Gross, G. G.; Bane, C. L.; Palmieri, F. M. North Central Cancer Treatment, G. Phase II Trial of Weekly Nab (Nanoparticle Albumin-Bound)-Paclitaxel (Nab-Paclitaxel) (Abraxane) in Combination with Gemcitabine in Patients with Metastatic Breast Cancer (N0531) Ann. Oncol. 2009, 20, 449-453
188. Moreno-Aspitia, A.; Perez, E. A. North Central Cancer Treatment Group N0531: Phase II Trial of Weekly Albumin-Bound Paclitaxel (ABI-007; Abraxane) in Combination with Gemcitabine in Patients with Metastatic Breast Cancer Clin. Breast Cancer 2005, 6, 361-364
189. Yardley, D. A.; Hart, L.; Bosserman, L.; Salleh, M. N.; Waterhouse, D. M.; Hagan, M. K.; Richards, P.; DeSilvio, M. L.; Mahoney, J. M.; Nagarwala, Y. Phase II Study Evaluating Lapatinib in Combination with Nab-Paclitaxel in Her2-Overexpressing Metastatic Breast Cancer Patients Who Have Received No More Than One Prior Chemotherapeutic Regimen Breast Cancer Res. Treat. 2013, 137, 457-464
190. Schwartzberg, L. S.; Arena, F. P.; Mintzer, D. M.; Epperson, A. L.; Walker, M. S. Phase II Multicenter Trial of Albumin-Bound Paclitaxel and Capecitabine in First-Line Treatment of Patients with Metastatic Breast Cancer Clin. Breast Cancer 2012, 12, 87-93
191. Hamilton, E.; Kimmick, G.; Hopkins, J.; Marcom, P. K.; Rocha, G.; Welch, R.; Broadwater, G.; Blackwell, K. Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer Clin. Breast Cancer 2013, 13, 416-420
192. Mirtsching, B.; Cosgriff, T.; Harker, G.; Keaton, M.; Chidiac, T.; Min, M. A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel with or without Trastuzumab in Metastatic Breast Cancer Clin. Breast Cancer 2011, 11, 121-128
193. Conlin, A. K.; Seidman, A. D.; Bach, A.; Lake, D.; Dickler, M.; DAndrea, G.; Traina, T.; Danso, M.; Brufsky, A. M.; Saleh, M. et al. Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel with Carboplatin and Trastuzumab as First-Line Therapy for Women with Her2-Overexpressing Metastatic Breast Cancer Clin. Breast Cancer 2010, 10, 281-287
194. Yardley, D. A.; Zubkus, J.; Daniel, B.; Inhorn, R.; Lane, C. M.; Vazquez, E. R.; Naot, Y.; Burris, H. A., III; Hainsworth, J. D. A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel with Pegfilgrastim in the Treatment of Patients with Locally Advanced Breast Cancer Clin. Breast Cancer 2010, 10, 367-272
195. Robidoux, A.; Buzdar, A. U.; Quinaux, E.; Jacobs, S.; Rastogi, P.; Fourchotte, V.; Younan, R. J.; Pajon, E. R.; Shalaby, I. A.; Desai, A. M. et al. A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer Clin. Breast Cancer 2010, 10, 81-86
196. +Breast Cancer Clin. Breast Cancer 2011, 11, 297-305
197. Yardley, D.; Burris, H., III; Peacock, N.; Raefsky, E.; Melnik, M.; Inhorn, R.; Shipley, D.; Hainsworth, J. A Pilot Study of Adjuvant Nanoparticle Albumin-Bound (Nab) Paclitaxel and Cyclophosphamide, with Trastuzumab in Her2-Positive Patients, in the Treatment of Early-Stage Breast Cancer Breast Cancer Res. Treat. 2010, 123, 471-475
198. Kaklamani, V. G.; Siziopikou, K.; Scholtens, D.; Lacouture, M.; Gordon, J.; Uthe, R.; Meservey, C.; Hansen, N.; Khan, S. A.; Jeruss, J. S. et al. Pilot Neoadjuvant Trial in Her2 Positive Breast Cancer with Combination of Nab-Paclitaxel and Lapatinib Breast Cancer Res. Treat. 2012, 132, 833-842
199. McArthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S. et al. A Feasibility Study of Bevacizumab Plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer Clin. Cancer Res. 2011, 17, 3398-3407
200. Robert, N.; Krekow, L.; Stokoe, C.; Clawson, A.; Iglesias, J.; OShaughnessy, J. Adjuvant Dose-Dense Doxorubicin Plus Cyclophosphamide Followed by Dose-Dense Nab-Paclitaxel Is Safe in Women with Early-Stage Breast Cancer: A Pilot Study Breast Cancer Res. Treat. 2011, 125, 115-120
201. Coleman, R. L.; Brady, W. E.; McMeekin, D. S.; Rose, P. G.; Soper, J. T.; Lentz, S. S.; Hoffman, J. S.; Shahin, M. S. A Phase II Evaluation of Nanoparticle, Albumin-Bound (Nab) Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study Gynecol. Oncol. 2011, 122, 111-115
202. Teneriello, M. G.; Tseng, P. C.; Crozier, M.; Encarnacion, C.; Hancock, K.; Messing, M. J.; Boehm, K. A.; Williams, A.; Asmar, L. Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients with Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer J. Clin. Oncol. 2009, 27, 1426-1431
203. Stinchcombe, T. E.; Socinski, M. A.; Walko, C. M.; ONeil, B. H.; Collichio, F. A.; Ivanova, A.; Mu, H.; Hawkins, M. J.; Goldberg, R. M.; Lindley, C. et al. Phase I and Pharmacokinetic Trial of Carboplatin and Albumin-Bound Paclitaxel, ABI-007 (Abraxane) on Three Treatment Schedules in Patients with Solid Tumors Cancer Chemother. Pharmacol. 2007, 60, 759-766
204. Tillmanns, T. D.; Lowe, M. P.; Walker, M. S.; Stepanski, E. J.; Schwartzberg, L. S. Phase II Clinical Trial of Bevacizumab with Albumin-Bound Paclitaxel in Patients with Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma Gynecol. Oncol. 2013, 128, 221-228
205. Stinchcombe, T. E.; Socinski, M. A.; Lee, C. B.; Hayes, D. N.; Moore, D. T.; Goldberg, R. M.; Dees, E. C. Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies J. Thorac. Oncol. 2008, 3, 521-526
206. Ho, C.; Davies, A. M.; Sangha, R. S.; Lau, D.; Lara, P., Jr.; Chew, H. K.; Beckett, L.; Mack, P. C.; Riess, J. W.; Gandara, D. R. Phase I/II Trial of Pemetrexed Plus Nab-Paclitaxel in Advanced Solid Tumor Patients with Emphasis on Non-Small Cell Lung Cancer Invest. New Drugs 2013, 31, 1587-1591
207. Reynolds, C.; Barrera, D.; Jotte, R.; Spira, A. I.; Weissman, C.; Boehm, K. A.; Pritchard, S.; Asmar, L. Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-Line Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer J. Thorac. Oncol. 2009, 4, 1537-1543
208. Kottschade, L. A.; Suman, V. J.; Amatruda, T., III; McWilliams, R. R.; Mattar, B. I.; Nikcevich, D. A.; Behrens, R.; Fitch, T. R.; Jaslowski, A. J.; Markovic, S. N. A Phase II Trial of Nab-paclitaxel (ABI-007) and Carboplatin in Patients with Unresectable Stage IV Melanoma: A North Central Cancer Treatment Group Study, N057E(1) Cancer 2011, 117, 1704-1710
209. Kottschade, L. A.; Suman, V. J.; Perez, D. G.; McWilliams, R. R.; Kaur, J. S.; Amatruda, T. T., III; Geoffroy, F. J.; Gross, H. M.; Cohen, P. A.; Jaslowski, A. J. et al. A Randomized Phase 2 Study of Temozolomide and Bevacizumab or Nab-Paclitaxel, Carboplatin, and Bevacizumab in Patients with Unresectable Stage IV Melanoma: A North Central Cancer Treatment Group Study, N0775 Cancer 2013, 119, 586-592
210. Ott, P. A.; Chang, J.; Madden, K.; Kannan, R.; Muren, C.; Escano, C.; Cheng, X.; Shao, Y.; Mendoza, S.; Gandhi, A. et al. Oblimersen in Combination with Temozolomide and Albumin-Bound Paclitaxel in Patients with Advanced Melanoma: A Phase I Trial Cancer Chemother. Pharmacol. 2013, 71, 183-191
211. Ko, A. H.; Truong, T. G.; Kantoff, E.; Jones, K. A.; Dito, E.; Ong, A.; Tempero, M. A. A Phase I Trial of Nab-Paclitaxel, Gemcitabine, and Capecitabine for Metastatic Pancreatic Cancer Cancer Chemother. Pharmacol. 2012, 70, 875-881
212. Tsimberidou, A. M.; Ye, Y.; Wheler, J.; Naing, A.; Hong, D.; Nwosu, U.; Hess, K. R.; Wolff, R. A. A Phase I Study of Hepatic Arterial Infusion of Nab-Paclitaxel in Combination with Intravenous Gemcitabine and Bevacizumab for Patients with Advanced Cancers and Predominant Liver Metastases Cancer Chemother. Pharmacol. 2013, 71, 955-963
213. Sasaki, Y.; Nishina, T.; Yasui, H.; Goto, M.; Muro, K.; Tsuji, A.; Koizumi, W.; Toh, Y.; Hara, T.; Miyata, Y. Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel as Second-Line Chemotherapy for Unresectable or Recurrent Gastric Cancer Cancer Sci. 2014, 105, 812-817
214. Ko, Y. J.; Canil, C. M.; Mukherjee, S. D.; Winquist, E.; Elser, C.; Eisen, A.; Reaume, M. N.; Zhang, L.; Sridhar, S. S. Nanoparticle Albumin-Bound Paclitaxel for Second-Line Treatment of Metastatic Urothelial Carcinoma: A Single Group, Multicentre, Phase 2 Study Lancet Oncol. 2013, 14, 769-776
215. McKiernan, J. M.; Barlow, L. J.; Laudano, M. A.; Mann, M. J.; Petrylak, D. P.; Benson, M. C. A Phase I Trial of Intravesical Nanoparticle Albumin-Bound Paclitaxel in the Treatment of Bacillus Calmette-Guerin Refractory Nonmuscle Invasive Bladder Cancer J. Urol. 2011, 186, 448-451
216. Shepard, D. R.; Dreicer, R.; Garcia, J.; Elson, P.; Magi-Galluzzi, C.; Raghavan, D.; Stephenson, A. J.; Klein, E. A. Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients with Prostate Cancer Undergoing Radical Prostatectomy J. Urol. 2009, 181, 1672-1677
217. Hansel, D. E.; Platt, E.; Orloff, M.; Harwalker, J.; Sethu, S.; Hicks, J. L.; De Marzo, A.; Steinle, R. E.; Hsi, E. D.; Theodorescu, D. et al. Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma Am. J. Pathol. 2010, 176, 3062-3072
218. Baselga, J.; Campone, M.; Piccart, M.; Burris, H. A., III; Rugo, H. S.; Sahmoud, T.; Noguchi, S.; Gnant, M.; Pritchard, K. I.; Lebrun, F. et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer N. Engl. J. Med. 2012, 366, 520-529
219. Yao, J. C.; Shah, M. H.; Ito, T.; Bohas, C. L.; Wolin, E. M.; Van Cutsem, E.; Hobday, T. J.; Okusaka, T.; Capdevila, J.; de Vries, E. G. et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors N. Engl. J. Med. 2011, 364, 514-523
220. Seront, E.; Rottey, S.; Sautois, B.; Kerger, J.; DHondt, L. A.; Verschaeve, V.; Canon, J. L.; Dopchie, C.; Vandenbulcke, J. M.; Whenham, N. et al. Phase II Study of Everolimus in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract: Clinical Activity, Molecular Response, and Biomarkers Ann. Oncol. 2012, 23, 2663-2670
221. Yuan, R.; Kay, A.; Berg, W. J.; Lebwohl, D. Targeting Tumorigenesis: Development and Use of mTOR Inhibitors in Cancer Therapy J. Hematol. Oncol. 2009, 2, 45
222. Cirstea, D.; Hideshima, T.; Rodig, S.; Santo, L.; Pozzi, S.; Vallet, S.; Ikeda, H.; Perrone, G.; Gorgun, G.; Patel, K. et al. Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound-Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma Mol. Cancer Ther. 2010, 9, 963-975
223. Gonzalez-Angulo, A. M.; Meric-Bernstam, F.; Chawla, S.; Falchook, G.; Hong, D.; Akcakanat, A.; Chen, H.; Naing, A.; Fu, S.; Wheler, J. et al. Weekly Nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial Clin. Cancer Res. 2013, 19, 5474-5484
224. Seymour, L. W.; Ferry, D. R.; Anderson, D.; Hesslewood, S.; Julyan, P. J.; Poyner, R.; Doran, J.; Young, A. M.; Burtles, S.; Kerr, D. J. et al. Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin J. Clin. Oncol. 2002, 20, 1668-1676
225. Melancon, M. P.; Li, C. Multifunctional Synthetic Poly(L-Glutamic Acid)-Based Cancer Therapeutic and Imaging Agents Mol. Imaging 2011, 10, 28-42
226. Kopecek, J. Polymer-Drug Conjugates: Origins, Progress to Date and Future Directions Adv. Drug Delivery Rev. 2013, 65, 49-59
227. Duncan, R.; Vicent, M. J. Polymer Therapeutics-Prospects for 21st Century: The End of the Beginning Adv. Drug Delivery Rev. 2013, 65, 60-70
228. Pasut, G.; Veronese, F. M. PEG Conjugates in Clinical Development or Use as Anticancer Agents: An Overview Adv. Drug Delivery Rev. 2009, 61, 1177-1188
229. Duncan, R. Polymer Conjugates as Anticancer Nanomedicines Nat. Rev. Cancer 2006, 6, 688-701
230. Li, C.; Wallace, S. Polymer-Drug Conjugates: Recent Development in Clinical Oncology Adv. Drug Delivery Rev. 2008, 60, 886-898
231. Li, C.; Yu, D. F.; Newman, R. A.; Cabral, F.; Stephens, L. C.; Hunter, N.; Milas, L.; Wallace, S. Complete Regression of Well-Established Tumors Using a Novel Water-Soluble Poly(L-Glutamic Acid)-Paclitaxel Conjugate Cancer Res. 1998, 58, 2404-2409
232. Li, C.; Price, J. E.; Milas, L.; Hunter, N. R.; Ke, S.; Yu, D. F.; Charnsangavej, C.; Wallace, S. Antitumor Activity of Poly(L-Glutamic Acid)-Paclitaxel on Syngeneic and Xenografted Tumors Clin. Cancer Res. 1999, 5, 891-897
233. Oldham, E. A.; Li, C.; Ke, S.; Wallace, S.; Huang, P. Comparison of Action of Paclitaxel and Poly(L-Glutamic Acid)-Paclitaxel Conjugate in Human Breast Cancer Cells Int. J. Oncol. 2000, 16, 125-132
234. Li, C.; Newman, R. A.; Wu, Q. P.; Ke, S.; Chen, W.; Hutto, T.; Kan, Z.; Brannan, M. D.; Charnsangavej, C.; Wallace, S. Biodistribution of Paclitaxel and Poly(L-Glutamic Acid)-Paclitaxel Conjugate in Mice with Ovarian OCA-1 Tumor Cancer Chemother. Pharmacol. 2000, 46, 416-422
235. Zou, Y.; Wu, Q. P.; Tansey, W.; Chow, D.; Hung, M. C.; Charnsangavej, C.; Wallace, S.; Li, C. Effectiveness of Water Soluble Poly(L-Glutamic Acid)-Camptothecin Conjugate against Resistant Human Lung Cancer Xenografted in Nude Mice Int. J. Oncol. 2001, 18, 331-336
236. Veronese, M. L.; Flaherty, K.; Kramer, A.; Konkle, B. A.; Morgan, M.; Stevenson, J. P.; ODwyer, P. J. Phase I Study of the Novel Taxane CT-2103 in Patients with Advanced Solid Tumors Cancer Chemother. Pharmacol. 2005, 55, 497-501
237. Boddy, A. V.; Plummer, E. R.; Todd, R.; Sludden, J.; Griffin, M.; Robson, L.; Cassidy, J.; Bissett, D.; Bernareggi, A.; Verrill, M. W. et al. A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules Clin. Cancer Res. 2005, 11, 7834-7840
238. Richards, D. A.; Richards, P.; Bodkin, D.; Neubauer, M. A.; Oldham, F. Efficacy and Safety of Paclitaxel Poliglumex as First-Line Chemotherapy in Patients at High Risk with Advanced-Stage Non-Small-Cell Lung Cancer: Results of a Phase II Study Clin. Lung Cancer 2005, 7, 215-220
239. Paz-Ares, L.; Ross, H.; OBrien, M.; Riviere, A.; Gatzemeier, U.; Von Pawel, J.; Kaukel, E.; Freitag, L.; Digel, W.; Bischoff, H. et al. Phase III Trial Comparing Paclitaxel Poliglumex vs Docetaxel in the Second-Line Treatment of Non-Small-Cell Lung Cancer Br. J. Cancer 2008, 98, 1608-1613
240. OBrien, M. E.; Socinski, M. A.; Popovich, A. Y.; Bondarenko, I. N.; Tomova, A.; Bilynsky, B. T.; Hotko, Y. S.; Ganul, V. L.; Kostinsky, I. Y.; Eisenfeld, A. J. et al. Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer J. Thorac. Oncol. 2008, 3, 728-734
241. Langer, C. J.; OByrne, K. J.; Socinski, M. A.; Mikhailov, S. M.; Lesniewski-Kmak, K.; Smakal, M.; Ciuleanu, T. E.; Orlov, S. V.; Dediu, M.; Heigener, D. et al. Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer J. Thorac. Oncol. 2008, 3, 623-630
242. du Bois, A.; Quinn, M.; Thigpen, T.; Vermorken, J.; Avall-Lundqvist, E.; Bookman, M.; Bowtell, D.; Brady, M.; Casado, A.; Cervantes, A. et al. 2004 Consensus Statements on the Management of Ovarian Cancer: Final Document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (Gcig Occc 2004) Ann. Oncol. 2005, 16, viii7-viii12
243. Nemunaitis, J.; Cunningham, C.; Senzer, N.; Gray, M.; Oldham, F.; Pippen, J.; Mennel, R.; Eisenfeld, A. Phase I Study of CT-2103, a Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors Cancer Invest. 2005, 23, 671-676
244. Verschraegen, C. F.; Skubitz, K.; Daud, A.; Kudelka, A. P.; Rabinowitz, I.; Allievi, C.; Eisenfeld, A.; Singer, J. W.; Oldham, F. B. A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex and Cisplatin in Patients with Advanced Solid Tumors Cancer Chemother. Pharmacol. 2009, 63, 903-910
245. Morgan, M. A.; Darcy, K. M.; Rose, P. G.; DeGeest, K.; Bookman, M. A.; Aikins, J. K.; Sill, M. W.; Mannel, R. S.; Allievi, C.; Egorin, M. J. et al. Paclitaxel Poliglumex and Carboplatin as First-Line Therapy in Ovarian, Peritoneal or Fallopian Tube Cancer: A Phase I and Feasibility Trial of the Gynecologic Oncology Group Gynecol. Oncol. 2008, 110, 329-335
246. Sabbatini, P.; Sill, M. W.; OMalley, D.; Adler, L.; Secord, A. A. Gynecologic Oncology Group, S. A Phase II Trial of Paclitaxel Poliglumex in Recurrent or Persistent Ovarian or Primary Peritoneal Cancer (EOC): A Gynecologic Oncology Group Study Gynecol. Oncol. 2008, 111, 455-460
247. Sabbatini, P.; Aghajanian, C.; Dizon, D.; Anderson, S.; Dupont, J.; Brown, J. V.; Peters, W. A.; Jacobs, A.; Mehdi, A.; Rivkin, S. et al. Phase II Study of CT-2103 in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma J. Clin. Oncol. 2004, 22, 4523-4531
248. Li, C.; Ke, S.; Wu, Q. P.; Tansey, W.; Hunter, N.; Buchmiller, L. M.; Milas, L.; Charnsangavej, C.; Wallace, S. Tumor Irradiation Enhances the Tumor-Specific Distribution of Poly(L-Glutamic Acid)-Conjugated Paclitaxel and Its Antitumor Efficacy Clin. Cancer Res. 2000, 6, 2829-2834
249. Milas, L.; Mason, K. A.; Hunter, N.; Li, C.; Wallace, S. Poly(L-Glutamic Acid)-Paclitaxel Conjugate Is a Potent Enhancer of Tumor Radiocurability Int. J. Radiat. Oncol., Biol., Phys. 2003, 55, 707-712
250. Dipetrillo, T.; Milas, L.; Evans, D.; Akerman, P.; Ng, T.; Miner, T.; Cruff, D.; Chauhan, B.; Iannitti, D.; Harrington, D. et al. Paclitaxel Poliglumex (PPX-XYOTAX) and Concurrent Radiation for Esophageal and Gastric Cancer: A Phase I Study Am. J. Clin. Oncol. 2006, 29, 376-379
251. Dipetrillo, T.; Suntharalingam, M.; Ng, T.; Fontaine, J.; Horiba, N.; Oldenburg, N.; Perez, K.; Birnbaum, A.; Battafarano, R.; Burrows, W. et al. Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer: A Phase 2 Trial Am. J. Clin. Oncol. 2012, 35, 64-67
252. Jeyapalan, S.; Boxerman, J.; Donahue, J.; Goldman, M.; Kinsella, T.; Dipetrillo, T.; Evans, D.; Elinzano, H.; Constantinou, M.; Stopa, E. et al. Paclitaxel Poliglumex, Temozolomide, and Radiation for Newly Diagnosed High-Grade Glioma: A Brown University Oncology Group Study Am. J. Clin. Oncol. 2014, 37, 444-449
253. Duncan, R.; Coatsworth, J. K.; Burtles, S. Preclinical Toxicology of a Novel Polymeric Antitumour Agent: HPMA Copolymer-doxorubicin (PK1) Hum. Exp. Toxicol. 1998, 17, 93-104
254. Ulbrich, K.; Etrych, T.; Chytil, P.; Jelinkova, M.; Rihova, B. HPMA Copolymers with pH-controlled Release of Doxorubicin-In Vitro Cytotoxicity and In Vivo Antitumor Activity J. Controlled Release 2003, 87, 33-47
255. Rihova, B.; Etrych, T.; Pechar, M.; Jelinkova, M.; Stastny, M.; Hovorka, O.; Kovar, M.; Ulbrich, K. Doxorubicin Bound to a HPMA Copolymer Carrier Through Hydrazone Bond Is Effective Also in a Cancer Cell Line with a Limited Content of Lysosomes J. Controlled Release 2001, 74, 225-232
256. Vasey, P. A.; Kaye, S. B.; Morrison, R.; Twelves, C.; Wilson, P.; Duncan, R.; Thomson, A. H.; Murray, L. S.; Hilditch, T. E.; Murray, T. et al. Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents-Drug-Polymer Conjugates Clin. Cancer Res. 1999, 5, 83-94
257. Seymour, L. W.; Ferry, D. R.; Kerr, D. J.; Rea, D.; Whitlock, M.; Poyner, R.; Boivin, C.; Hesslewood, S.; Twelves, C.; Blackie, R. et al. Phase II studies of polymer-doxtubincin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer Int. J. Oncol. 2009, 34, 1629-1636
258. Hopewell, J. W.; Duncan, R.; Wilding, D.; Chakrabarti, K. Preclinical Evaluation of the Cardiotoxicity of PK2: A Novel HPMA Copolymer-Doxorubicin-Galactosamine Conjugate Antitumour Agent Hum. Exp. Toxicol. 2001, 20, 461-470
259. Svenson, S.; Wolfgang, M.; Hwang, J.; Ryan, J.; Eliasof, S. Preclinical to Clinical Development of the Novel Camptothecin Nanopharmaceutical CRLX101 J. Controlled Release 2011, 153, 49-55
260. Schluep, T.; Cheng, J.; Khin, K. T.; Davis, M. E. Pharmacokinetics and Biodistribution of the Camptothecin-Polymer Conjugate IT-101 in Rats and Tumor-Bearing Mice Cancer Chemother. Pharmacol. 2006, 57, 654-662
261. Schluep, T.; Hwang, J.; Cheng, J.; Heidel, J. D.; Bartlett, D. W.; Hollister, B.; Davis, M. E. Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models Clin. Cancer Res. 2006, 12, 1606-1614
262. Numbenjapon, T.; Wang, J.; Colcher, D.; Schluep, T.; Davis, M. E.; Duringer, J.; Kretzner, L.; Yen, Y.; Forman, S. J.; Raubitschek, A. Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models Clin. Cancer Res. 2009, 15, 4365-4373
263. Gaur, S.; Chen, L.; Yen, T.; Wang, Y.; Zhou, B.; Davis, M.; Yen, Y. Preclinical Study of the Cyclodextrin-polymer Conjugate of Camptothecin CRLX101 for the Treatment of Gastric Cancer Nanomedicine 2012, 8, 721-730
264. Weiss, G. J.; Chao, J.; Neidhart, J. D.; Ramanathan, R. K.; Bassett, D.; Neidhart, J. A.; Choi, C. H.; Chow, W.; Chung, V.; Forman, S. J. et al. First-in-Human Phase 1/2a Trial of CRX101, a Cyclodextrin-Containing Polymer-Camptothecin Nanopharmaceutical in Patients with Advanced Solid Tumor Malignancies Invest. New Drugs 2013, 31, 986-1000
265. Gaur, S.; Wang, Y.; Kretzner, L.; Chen, L.; Yen, T.; Wu, X.; Yuan, Y. C.; Davis, M.; Yen, Y. Pharmacodynamic and Pharmacogenomic Study of the Nanoparticle Conjugate of Camptothecin CRLX101 for the Treatment of Cancer Nanomedicine 2014, 10, 1477-1486
266. http://www.ceruleanrx.com/platform-pipeline/crlx301.php.
267. Kim, S. C.; Kim, D. W.; Shim, Y. H.; Bang, J. S.; Oh, H. S.; Wan Kim, S.; Seo, M. H. In Vivo Evaluation of Polymeric Micellar Paclitaxel Formulation: Toxicity and Efficacy J. Controlled Release 2001, 72, 191-202
268. Kim, T. Y.; Kim, D. W.; Chung, J. Y.; Shin, S. G.; Kim, S. C.; Heo, D. S.; Kim, N. K.; Bang, Y. J. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies Clin. Cancer Res. 2004, 10, 3708-3716
269. Lim, W. T.; Tan, E. H.; Toh, C. K.; Hee, S. W.; Leong, S. S.; Ang, P. C.; Wong, N. S.; Chowbay, B. Phase I Pharmacokinetic Study of a Weekly Liposomal Paclitaxel Formulation (Genexol-PM) in Patients with Solid Tumors Ann. Oncol. 2010, 21, 382-388
270. Lee, K. S.; Chung, H. C.; Im, S. A.; Park, Y. H.; Kim, C. S.; Kim, S. B.; Rha, S. Y.; Lee, M. Y.; Ro, J. Multicenter Phase II Trial of Genexol-PM, a Cremophor-Free, Polymeric Micelle Formulation of Paclitaxel, in Patients with Metastatic Breast Cancer Breast Cancer Res. Treat. 2008, 108, 241-250
271. Kim, D. W.; Kim, S. Y.; Kim, H. K.; Kim, S. W.; Shin, S. W.; Kim, J. S.; Park, K.; Lee, M. Y.; Heo, D. S. Multicenter Phase II Trial of Genexol-PM, a Novel Cremophor-Free, Polymeric Micelle Formulation of Paclitaxel, with Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer Ann. Oncol. 2007, 18, 2009-2014
272. Ahn, H. K.; Jung, M.; Sym, S. J.; Shin, D. B.; Kang, S. M.; Kyung, S. Y.; Park, J. W.; Jeong, S. H.; Cho, E. K. A Phase II Trial of Cremorphor EL-Free Paclitaxel (Genexol-PM) and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer Cancer Chemother. Pharmacol. 2014, 74, 277-282
273. Matsumura, Y. Preclinical and Clinical Studies of NK012, an SN-38-Incorporating Polymeric Micelles, Which Is Designed Based on EPR Effect Adv. Drug Delivery Rev. 2011, 63, 184-192
274. Nakajima, T. E.; Yasunaga, M.; Kano, Y.; Koizumi, F.; Kato, K.; Hamaguchi, T.; Yamada, Y.; Shirao, K.; Shimada, Y.; Matsumura, Y. Synergistic Antitumor Activity of the Novel SN-38-Incorporating Polymeric Micelles, NK012, Combined with 5-Fluorouracil in a Mouse Model of Colorectal Cancer, as Compared with That of Irinotecan Plus 5-Fluorouracil Int. J. Cancer 2008, 122, 2148-2153
275. Sumitomo, M.; Koizumi, F.; Asano, T.; Horiguchi, A.; Ito, K.; Asano, T.; Kakizoe, T.; Hayakawa, M.; Matsumura, Y. Novel SN-38-Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression Cancer Res. 2008, 68, 1631-1635
276. Kuroda, J.; Kuratsu, J.; Yasunaga, M.; Koga, Y.; Saito, Y.; Matsumura, Y. Potent Antitumor Effect of SN-38-Incorporating Polymeric Micelle, NK012, against Malignant Glioma Int. J. Cancer 2009, 124, 2505-2511
277. Yanagihara, K.; Takigahira, M.; Kubo, T.; Ochiya, T.; Hamaguchi, T.; Matsumura, Y. Marked Antitumor Effect of NK012, a SN-38-Incorporating Micelle Formulation, in a Newly Developed Mouse Model of Liver Metastasis Resulting from Gastric Cancer Ther. Delivery 2014, 5, 129-138
278. Hamaguchi, T.; Doi, T.; Eguchi-Nakajima, T.; Kato, K.; Yamada, Y.; Shimada, Y.; Fuse, N.; Ohtsu, A.; Matsumoto, S.; Takanashi, M. et al. Phase I Study of NK012, a Novel SN-38-Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors Clin. Cancer Res. 2010, 16, 5058-5066
279. Negishi, T.; Koizumi, F.; Uchino, H.; Kuroda, J.; Kawaguchi, T.; Naito, S.; Matsumura, Y. NK105, a Paclitaxel-Incorporating Micellar Nanoparticle, Is a More Potent Radiosensitising Agent Compared to Free Paclitaxel Br. J. Cancer 2006, 95, 601-606
280. Hamaguchi, T.; Matsumura, Y.; Suzuki, M.; Shimizu, K.; Goda, R.; Nakamura, I.; Nakatomi, I.; Yokoyama, M.; Kataoka, K.; Kakizoe, T. NK105, a Paclitaxel-Incorporating Micellar Nanoparticle Formulation, Can Extend in Vivo Antitumour Activity and Reduce the Neurotoxicity of Paclitaxel Br. J. Cancer 2005, 92, 1240-1246
281. Alakhova, D. Y.; Zhao, Y.; Li, S.; Kabanov, A. V. Effect of Doxorubicin/Pluronic SP1049C on Tumorigenicity, Aggressiveness, DNA Methylation and Stem Cell Markers in Murine Leukemia PLoS One 2013, 8, e72238
282. Sharma, A. K.; Zhang, L.; Li, S.; Kelly, D. L.; Alakhov, V. Y.; Batrakova, E. V.; Kabanov, A. V. Prevention of MDR Development in Leukemia Cells by Micelle-Forming Polymeric Surfactant J. Controlled Release 2008, 131, 220-227
283. Batrakova, E. V.; Dorodnych, T. Y.; Klinskii, E. Y.; Kliushnenkova, E. N.; Shemchukova, O. B.; Goncharova, O. N.; Arjakov, S. A.; Alakhov, V. Y.; Kabanov, A. V. Anthracycline Antibiotics Non-Covalently Incorporated into the Block Copolymer Micelles: In Vivo Evaluation of Anti-Cancer Activity Br. J. Cancer 1996, 74, 1545-1552
284. Danson, S.; Ferry, D.; Alakhov, V.; Margison, J.; Kerr, D.; Jowle, D.; Brampton, M.; Halbert, G.; Ranson, M. Phase I Dose Escalation and Pharmacokinetic Study of Pluronic Polymer-Bound Doxorubicin (SP1049C) in Patients with Advanced Cancer Br. J. Cancer 2004, 90, 2085-2091
285. Valle, J. W.; Armstrong, A.; Newman, C.; Alakhov, V.; Pietrzynski, G.; Brewer, J.; Campbell, S.; Corrie, P.; Rowinsky, E. K.; Ranson, M. A Phase 2 Study of SP1049C, Doxorubicin in P-Glycoprotein-Targeting Pluronics, in Patients with Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction Invest. New Drugs 2011, 29, 1029-1037
286. Hrkach, J.; Von Hoff, D.; Mukkaram Ali, M.; Andrianova, E.; Auer, J.; Campbell, T.; De Witt, D.; Figa, M.; Figueiredo, M.; Horhota, A. et al. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile Sci. Transl. Med. 2012, 4, 128ra139
287. Jin, J.; Sui, B.; Gou, J.; Liu, J.; Tang, X.; Xu, H.; Zhang, Y.; Jin, X. PSMA Ligand Conjugated PCL-PEG Polymeric Micelles Targeted to Prostate Cancer Cells PLoS One 2014, 9, e112200
288. Summa, J.; LoRusso, P. M.; Eisenberg, P.; Hrkach, J.; Schnipper, E.; Hoff, D. V. Abstract Lb-452: A Phase I, Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of Bind-014 Given by IV Infusion to Patients with Advanced or Metastatic Cancer Cancer Res. 2012, 72, LB-452
289. Mita, M.; Burris, H.; LoRusso, P.; Hart, L.; Eisenberg, P.; Mita, A.; Low, S.; Summa, J.; Berk, G.; Sachdev, J. Abstract CT210: A Phase 1 Study of Bind-014, a Psma-Targeted Nanoparticle Containing Docetaxel, Administered to Patients with Refractory Solid Tumors on a Weekly Schedule Cancer Res. 2014, 74, CT210
290. Uchino, H.; Matsumura, Y.; Negishi, T.; Koizumi, F.; Hayashi, T.; Honda, T.; Nishiyama, N.; Kataoka, K.; Naito, S.; Kakizoe, T. Cisplatin-Incorporating Polymeric Micelles (NC-6004) Can Reduce Nephrotoxicity and Neurotoxicity of Cisplatin in Rats Br. J. Cancer 2005, 93, 678-687
291. Baba, M.; Matsumoto, Y.; Kashio, A.; Cabral, H.; Nishiyama, N.; Kataoka, K.; Yamasoba, T. Micellization of Cisplatin (NC-6004) Reduces Its Ototoxicity in Guinea Pigs J. Controlled Release 2012, 157, 112-117
292. Endo, K.; Ueno, T.; Kondo, S.; Wakisaka, N.; Murono, S.; Ito, M.; Kataoka, K.; Kato, Y.; Yoshizaki, T. Tumor-Targeted Chemotherapy with the Nanopolymer-Based Drug NC-6004 for Oral Squamous Cell Carcinoma Cancer Sci. 2013, 104, 369-374
293. Plummer, R.; Wilson, R. H.; Calvert, H.; Boddy, A. V.; Griffin, M.; Sludden, J.; Tilby, M. J.; Eatock, M.; Pearson, D. G.; Ottley, C. J. et al. Phase I Clinical Study of Cisplatin-Incorporated Polymeric Micelles (NC-6004) in Patients with Solid Tumours Br. J. Cancer 2011, 104, 593-598
294. Degardin, M.; Cappelaere, P.; Krakowski, I.; Fargeot, P.; Cupissol, D.; Brienza, S. Phase II Trial of Oxaliplatin (L-OHP) in Advanced, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck EJC, Part B: Oral Oncol. 1996, 32B, 278-279
295. Ueno, T.; Endo, K.; Hori, K.; Ozaki, N.; Tsuji, A.; Kondo, S.; Wakisaka, N.; Murono, S.; Kataoka, K.; Kato, Y. et al. Assessment of Antitumor Activity and Acute Peripheral Neuropathy of 1,2-Diaminocyclohexane Platinum (II)-incorporating Micelles (NC-4016) Int. J. Nanomed. 2014, 9, 3005-3012
296. Yamamoto, Y.; Hyodo, I.; Takigahira, M.; Koga, Y.; Yasunaga, M.; Harada, M.; Hayashi, T.; Kato, Y.; Matsumura, Y. Effect of Combined Treatment with the Epirubicin-Incorporating Micelles (NC-6300) and 1,2-Diaminocyclohexane Platinum (II)-Incorporating Micelles (NC-4016) on a Human Gastric Cancer Model Int. J. Cancer 2014, 135, 214-223
297. Nakanishi, T.; Fukushima, S.; Okamoto, K.; Suzuki, M.; Matsumura, Y.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Kataoka, K. Development of the Polymer Micelle Carrier System for Doxorubicin J. Controlled Release 2001, 74, 295-302
298. Tsukioka, Y.; Matsumura, Y.; Hamaguchi, T.; Koike, H.; Moriyasu, F.; Kakizoe, T. Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil) Jpn. J. Cancer Res. 2002, 93, 1145-1153
299. Matsumura, Y.; Hamaguchi, T.; Ura, T.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Okusaka, T.; Ueno, H.; Ikeda, M. et al. Phase I Clinical Trial and Pharmacokinetic Evaluation of NK911, a Micelle-Encapsulated Doxorubicin Br. J. Cancer 2004, 91, 1775-1781
300. Kannan, R. M.; Nance, E.; Kannan, S.; Tomalia, D. A. Emerging Concepts in Dendrimer-Based Nanomedicine: From Design Principles to Clinical Applications J. Int. Med. 2014, 276, 579-617
301. Mignani, S.; El Kazzouli, S.; Bousmina, M.; Majoral, J. P. Expand Classical Drug Administration Ways by Emerging Routes Using Dendrimer Drug Delivery Systems: A Concise Overview Adv. Drug Delivery Rev. 2013, 65, 1316-1330
302. Venuganti, V. V.; Perumal, O. P. Poly(Amidoamine) Dendrimers as Skin Penetration Enhancers: Influence of Charge, Generation, and Concentration J. Pharm. Sci. 2009, 98, 2345-2356
303. Spataro, G.; Malecaze, F.; Turrin, C. O.; Soler, V.; Duhayon, C.; Elena, P. P.; Majoral, J. P.; Caminade, A. M. Designing Dendrimers for Ocular Drug Delivery Eur. J. Med. Chem. 2010, 45, 326-334
304. Lin, Y.; Fujimori, T.; Kawaguchi, N.; Tsujimoto, Y.; Nishimi, M.; Dong, Z.; Katsumi, H.; Sakane, T.; Yamamoto, A. Polyamidoamine Dendrimers as Novel Potential Absorption Enhancers for Improving the Small Intestinal Absorption of Poorly Absorbable Drugs in Rats J. Controlled Release 2011, 149, 21-28
305. Luscher-Mattli, M. Polyanions-a Lost Chance in the Fight against Hiv and Other Virus Diseases? Antiviral Chem. Chemother. 2000, 11, 249-259
306. Bernstein, D. I.; Stanberry, L. R.; Sacks, S.; Ayisi, N. K.; Gong, Y. H.; Ireland, J.; Mumper, R. J.; Holan, G.; Matthews, B.; McCarthy, T. et al. Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes Antimicrob. Agents Chemother. 2003, 47, 3784-3788
307. McCarthy, T. D.; Karellas, P.; Henderson, S. A.; Giannis, M.; OKeefe, D. F.; Heery, G.; Paull, J. R.; Matthews, B. R.; Holan, G. Dendrimers as Drugs: Discovery and Preclinical and Clinical Development of Dendrimer-Based Microbicides for HIV and STI Prevention Mol. Pharmaceutics 2005, 2, 312-318
308. Jiang, Y. H.; Emau, P.; Cairns, J. S.; Flanary, L.; Morton, W. R.; McCarthy, T. D.; Tsai, C. C. SPL7013 Gel as a Topical Microbicide for Prevention of Vaginal Transmission of SHIV89.6P in Macaques AIDS Res. Hum. Retroviruses 2005, 21, 207-213
309. Gong, E.; Matthews, B.; McCarthy, T.; Chu, J.; Holan, G.; Raff, J.; Sacks, S. Evaluation of Dendrimer SPL7013, a Lead Microbicide Candidate against Herpes Simplex Viruses Antiviral Res. 2005, 68, 139-146
310. OLoughlin, J.; Millwood, I. Y.; McDonald, H. M.; Price, C. F.; Kaldor, J. M.; Paull, J. R. Safety, Tolerability, and Pharmacokinetics of SPL7013 Gel (Vivagel): A Dose Ranging, Phase I Study Sex. Transm. Dis. 2010, 37, 100-104
311. Cohen, C. R.; Brown, J.; Moscicki, A. B.; Bukusi, E. A.; Paull, J. R.; Price, C. F.; Shiboski, S. A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (Vivagel) in Healthy Young Women Administered Twice Daily for 14 Days PLoS One 2011, 6, e16258
312. Moscicki, A. B.; Kaul, R.; Ma, Y.; Scott, M. E.; Daud, I. I.; Bukusi, E. A.; Shiboski, S.; Rebbapragada, A.; Huibner, S.; Cohen, C. R. Measurement of Mucosal Biomarkers in a Phase 1 Trial of Intravaginal 3% Starpharma LTD 7013 Gel (Vivagel) to Assess Expanded Safety J. Acquired Immune Defic. Syndr. 2012, 59, 134-140
313. Price, C. F.; Tyssen, D.; Sonza, S.; Davie, A.; Evans, S.; Lewis, G. R.; Xia, S.; Spelman, T.; Hodsman, P.; Moench, T. R. et al. SPL7013 Gel (Vivagel) Retains Potent HIV-1 and HSV-2 Inhibitory Activity Following Vaginal Administration in Humans PLoS One 2011, 6, e24095
314. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Vander Elst, L.; Muller, R. N. Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications Chem. Rev. 2008, 108, 2064-2110
315. Reddy, L. H.; Arias, J. L.; Nicolas, J.; Couvreur, P. Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications Chem. Rev. 2012, 112, 5818-5878
316. Leenders, W. Ferumoxtran-10 Advanced Magnetics IDrugs 2003, 6, 987-993
317. Seneterre, E.; Weissleder, R.; Jaramillo, D.; Reimer, P.; Lee, A. S.; Brady, T. J.; Wittenberg, J. Bone Marrow: Ultrasmall Superparamagnetic Iron Oxide for MR Imaging Radiology 1991, 179, 529-533
318. Tanoura, T.; Bernas, M.; Darkazanli, A.; Elam, E.; Unger, E.; Witte, M. H.; Green, A. MR Lymphography with Iron Oxide Compound AMI-227: Studies in Ferrets with Filariasis AJR, Am. J. Roentgenol. 1992, 159, 875-881
319. McLachlan, S. J.; Morris, M. R.; Lucas, M. A.; Fisco, R. A.; Eakins, M. N.; Fowler, D. R.; Scheetz, R. B.; Olukotun, A. Y. Phase I Clinical Evaluation of a New Iron Oxide MR Contrast Agent J. Magn. Reson. Imaging 1994, 4, 301-307
320. Bellin, M. F.; Roy, C.; Kinkel, K.; Thoumas, D.; Zaim, S.; Vanel, D.; Tuchmann, C.; Richard, F.; Jacqmin, D.; Delcourt, A. et al. Lymph Node Metastases: Safety and Effectiveness of MR Imaging with Ultrasmall Superparamagnetic Iron Oxide Particles-Initial Clinical Experience Radiology 1998, 207, 799-808
321. 2-Weighted Pulse Sequences Radiology 1991, 181, 449-453
322. Harisinghani, M. G.; Saini, S.; Hahn, P. F.; Weissleder, R.; Mueller, P. R. MR Imaging of Lymph Nodes in Patients with Primary Abdominal and Pelvic Malignancies Using Ultrasmall Superparamagnetic Iron Oxide (Combidex) Acad. Radiol. 1998, 5, S167-169
323. Ahlstrom, K. H.; Johansson, L. O.; Rodenburg, J. B.; Ragnarsson, A. S.; Akeson, P.; Borseth, A. Pulmonary MR Angiography with Ultrasmall Superparamagnetic Iron Oxide Particles as a Blood Pool Agent and a Navigator Echo for Respiratory Gating: Pilot Study Radiology 1999, 211, 865-869
324. Nguyen, B. C.; Stanford, W.; Thompson, B. H.; Rossi, N. P.; Kernstine, K. H.; Kern, J. A.; Robinson, R. A.; Amorosa, J. K.; Mammone, J. F.; Outwater, E. K. Multicenter Clinical Trial of Ultrasmall Superparamagnetic Iron Oxide in the Evaluation of Mediastinal Lymph Nodes in Patients with Primary Lung Carcinoma J. Magn. Reson. Imaging 1999, 10, 468-473
325. Mack, M. G.; Balzer, J. O.; Straub, R.; Eichler, K.; Vogl, T. J. Superparamagnetic Iron Oxide-Enhanced Mr Imaging of Head and Neck Lymph Nodes Radiology 2002, 222, 239-244
326. Harisinghani, M. G.; Barentsz, J.; Hahn, P. F.; Deserno, W. M.; Tabatabaei, S.; van de Kaa, C. H. de la Rosette, J.; Weissleder, R. Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer N. Engl. J. Med. 2003, 348, 2491-2499
327. Bernd, H.; De Kerviler, E.; Gaillard, S.; Bonnemain, B. Safety and Tolerability of Ultrasmall Superparamagnetic Iron Oxide Contrast Agent: Comprehensive Analysis of a Clinical Development Program Invest. Radiol. 2009, 44, 336-342
328. Thill, M.; Kurylcio, A.; Welter, R.; van Haasteren, V.; Grosse, B.; Berclaz, G.; Polkowski, W.; Hauser, N. The Central-European Sentimag Study: Sentinel Lymph Node Biopsy with Superparamagnetic Iron Oxide (SPIO) vs. Radioisotope Breast 2014, 23, 175-179
329. Jordan, A.; Wust, P.; Fahling, H.; John, W.; Hinz, A.; Felix, R. Inductive Heating of Ferrimagnetic Particles and Magnetic Fluids: Physical Evaluation of Their Potential for Hyperthermia Int. J. Hyperthermia 1993, 9, 51-68
330. Jordan, A.; Scholz, R.; Wust, P.; Fahling, H.; Krause, J.; Wlodarczyk, W.; Sander, B.; Vogl, T.; Felix, R. Effects of Magnetic Fluid Hyperthermia (MFH) on C3H Mammary Carcinoma in vivo Int. J. Hyperthermia 1997, 13, 587-605
331. 31P NMR Spectroscopy, HPLC and Cell Survival Analysis Int. J. Hyperthermia 1997, 13, 69-82
332. Johannsen, M.; Gneveckow, U.; Taymoorian, K.; Thiesen, B.; Waldofner, N.; Scholz, R.; Jung, K.; Jordan, A.; Wust, P.; Loening, S. A. Morbidity and Quality of Life During Thermotherapy Using Magnetic Nanoparticles in Locally Recurrent Prostate Cancer: Results of a Prospective Phase I Trial Int. J. Hyperthermia 2007, 23, 315-323
333. Maier-Hauff, K.; Ulrich, F.; Nestler, D.; Niehoff, H.; Wust, P.; Thiesen, B.; Orawa, H.; Budach, V.; Jordan, A. Efficacy and Safety of Intratumoral Thermotherapy Using Magnetic Iron-Oxide Nanoparticles Combined with External Beam Radiotherapy on Patients with Recurrent Glioblastoma Multiforme J. Neurooncol. 2011, 103, 317-324
334. Hahn, P. F.; Stark, D. D.; Lewis, J. M.; Saini, S.; Elizondo, G.; Weissleder, R.; Fretz, C. J.; Ferrucci, J. T. First Clinical Trial of a New Superparamagnetic Iron Oxide for Use as an Oral Gastrointestinal Contrast Agent in MR Imaging Radiology 1990, 175, 695-700
335. Haldemann Heusler, R. C.; Wight, E.; Marincek, B. Oral Superparamagnetic Contrast Agent (Ferumoxsil): Tolerance and Efficacy in Mr Imaging of Gynecologic Diseases J. Magn. Reson. Imaging 1995, 5, 385-391
336. Johnson, W. K.; Stoupis, C.; Torres, G. M.; Rosenberg, E. B.; Ros, P. R. Superparamagnetic Iron Oxide (SPIO) as an Oral Contrast Agent in Gastrointestinal (GI) Magnetic Resonance Imaging (MRI): Comparison with State-of-the-Art Computed Tomography (CT) Magn. Reson. Imaging 1996, 14, 43-49
337. Scheidler, J.; Heuck, A. F.; Meier, W.; Reiser, M. F. MIR of Pelvic Masses: Efficacy of the Rectal Superparamagnetic Contrast Agent Ferumoxsil J. Magn. Reson. Imaging 1997, 7, 1027-1032
338. Macdougall, I. C.; Tucker, B.; Thompson, J.; Tomson, C. R.; Baker, L. R.; Raine, A. E. A Randomized Controlled Study of Iron Supplementation in Patients Treated with Erythropoietin Kidney Int. 1996, 50, 1694-1699
339. Burns, D. L.; Pomposelli, J. J. Toxicity of Parenteral Iron Dextran Therapy Kidney Int. Suppl. 1999, 69, S119-124
340. Fishbane, S.; Ungureanu, V. D.; Maesaka, J. K.; Kaupke, C. J.; Lim, V.; Wish, J. The Safety of Intravenous Iron Dextran in Hemodialysis Patients Am. J. Kidney Dis. 1996, 28, 529-534
341. Hamstra, R. D.; Block, M. H.; Schocket, A. L. Intravenous Iron Dextran in Clinical Medicine JAMA, J. Am. Med. Assoc. 1980, 243, 1726-1731
342. Chertow, G. M.; Mason, P. D.; Vaage-Nilsen, O.; Ahlmen, J. On the Relative Safety of Parenteral Iron Formulations Nephrol., Dial., Transplant. 2004, 19, 1571-1575
343. Balakrishnan, V. S.; Rao, M.; Kausz, A. T.; Brenner, L.; Pereira, B. J.; Frigo, T. B.; Lewis, J. M. Physicochemical Properties of Ferumoxytol, a New Intravenous Iron Preparation Eur. J. Clin. Invest. 2009, 39, 489-496
344. Ersoy, H.; Jacobs, P.; Kent, C. K.; Prince, M. R. Blood Pool MR Angiography of Aortic Stent-Graft Endoleak AJR, Am. J. Roentgenol. 2004, 182, 1181-1186
345. Prince, M. R.; Zhang, H. L.; Chabra, S. G.; Jacobs, P.; Wang, Y. A Pilot Investigation of New Superparamagnetic Iron Oxide (Ferumoxytol) as a Contrast Agent for Cardiovascular MRI J. X-Ray Sci. Technol. 2003, 11, 231-240
346. Spinowitz, B. S.; Schwenk, M. H.; Jacobs, P. M.; Bolton, W. K.; Kaplan, M. R.; Charytan, C.; Galler, M. The Safety and Efficacy of Ferumoxytol Therapy in Anemic Chronic Kidney Disease Patients Kidney Int. 2005, 68, 1801-1807
347. Singh, A.; Patel, T.; Hertel, J.; Bernardo, M.; Kausz, A.; Brenner, L. Safety of Ferumoxytol in Patients with Anemia and Ckd Am. J. Kidney Dis. 2008, 52, 907-915
348. Spinowitz, B. S.; Kausz, A. T.; Baptista, J.; Noble, S. D.; Sothinathan, R.; Bernardo, M. V.; Brenner, L.; Pereira, B. J. Ferumoxytol for Treating Iron Deficiency Anemia in Ckd J. Am. Soc. Nephrol. 2008, 19, 1599-1605
349. Provenzano, R.; Schiller, B.; Rao, M.; Coyne, D.; Brenner, L.; Pereira, B. J. Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients Clin. J. Am. Soc. Nephrol. 2009, 4, 386-393
350. Vadhan-Raj, S.; Strauss, W.; Ford, D.; Bernard, K.; Boccia, R.; Li, J.; Allen, L. F. Efficacy and Safety of Iv Ferumoxytol for Adults with Iron Deficiency Anemia Previously Unresponsive to or Unable to Tolerate Oral Iron Am. J. Hematol. 2014, 89, 7-12
351. Hetzel, D.; Strauss, W.; Bernard, K.; Li, Z.; Urboniene, A.; Allen, L. F. A Phase III, Randomized, Open-Label Trial of Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients with a History of Unsatisfactory Oral Iron Therapy Am. J. Hematol. 2014, 89, 646-650
352. Lonnemark, M.; Hemmingsson, A.; Bach-Gansmo, T.; Ericsson, A.; Oksendal, A.; Nyman, R.; Moxnes, A. Effect of Superparamagnetic Particles as Oral Contrast Medium at Magnetic Resonance Imaging. A Phase I Clinical Study Acta Radiol. 1989, 30, 193-196
353. Oksendal, A. N.; Bach-Gansmo, T.; Jacobsen, T. F.; Eide, H.; Andrew, E. Oral Magnetic Particles. Results from Clinical Phase II Trials in 216 Patients Acta Radiol. 1993, 34, 187-193
354. Rinck, P. A.; Smevik, O.; Nilsen, G.; Klepp, O.; Onsrud, M.; Oksendal, A.; Borseth, A. Oral Magnetic Particles in Mr Imaging of the Abdomen and Pelvis Radiology 1991, 178, 775-779
355. Van Beers, B.; Grandin, C.; Jamart, J.; Demeure, R.; Jacobsen, T. F.; Pringot, J. Magnetic Resonance Imaging of Lower Abdominal and Pelvic Lesions: Assessment of Oral Magnetic Particles as an Intestinal Contrast Agent Eur. J. Radiol. 1992, 14, 252-257
356. Boraschi, P.; Braccini, G.; Gigoni, R.; Cartei, F.; Perri, G. MR Enteroclysis Using Iron Oxide Particles (Ferristene) as an Endoluminal Contrast Agent: An Open Phase III Trial Magn. Reson. Imaging 2004, 22, 1085-1095
357. Wallengren, N. O.; Holtas, S.; Andren-Sandberg, A.; Jonsson, E.; Kristoffersson, D. T.; McGill, S. Rectal Carcinoma: Double-Contrast MR Imaging for Preoperative Staging Radiology 2000, 215, 108-114
358. Wallengren, N. O.; Holtas, S.; Andren-Sandberg, A. Preoperative Staging of Rectal Carcinoma Using Double-Contrast MR Imaging. Technical Aspects and Early Clinical Experiences Acta Radiol. 1996, 37, 791-798
359. Blomqvist, L.; Ohlsen, H.; Hindmarsh, T.; Jonsson, E.; Holm, T. Local Recurrence of Rectal Cancer: Mr Imaging before and after Oral Superparamagnetic Particles vs Contrast-Enhanced Computed Tomography Eur. Radiol. 2000, 10, 1383-1389
360. 198in Man Cancer 1954, 7, 856-866
361. Rubin, P.; Levitt, S. H. The Response of Disseminated Reticulum Cell Sarcoma to the Intravenous Injection of Colloidal Radioactive Gold J. Nucl. Med. 1964, 5, 581-594
362. Dreaden, E. C.; Mackey, M. A.; Huang, X. H.; Kang, B.; El-Sayed, M. A. Beating Cancer in Multiple Ways Using Nanogold Chem. Soc. Rev. 2011, 40, 3391-3404
363. Hainfeld, J. F.; Slatkin, D. N.; Smilowitz, H. M. The Use of Gold Nanoparticles to Enhance Radiotherapy in Mice Phys. Med. Biol. 2004, 49, N309-N315
364. El-Sayed, I. H.; Huang, X. H.; El-Sayed, M. A. Selective Laser Photo-Thermal Therapy of Epithelial Carcinoma Using Anti-EGFR Antibody Conjugated Gold Nanoparticles Cancer Lett. 2006, 239, 129-135
365. von Maltzahn, G.; Park, J. H.; Agrawal, A.; Bandaru, N. K.; Das, S. K.; Sailor, M. J.; Bhatia, S. N. Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas Cancer Res. 2009, 69, 3892-3900
366. Huang, X. H.; Jain, P. K.; El-Sayed, I. H.; El-Sayed, M. A. Plasmonic Photothermal Therapy (PPTT) Using Gold Nanoparticles Laser Med. Sci. 2008, 23, 217-228
367. Paciotti, G. F.; Myer, L.; Weinreich, D.; Goia, D.; Pavel, N.; McLaughlin, R. E.; Tamarkin, L. Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery Drug Delivery 2004, 11, 169-183
368. Conde, J.; Ambrosone, A.; Sanz, V.; Hernandez, Y.; Marchesano, V.; Tian, F. R.; Child, H.; Berry, C. C.; Ibarra, M. R.; Baptista, P. V. et al. Design of Multifunctional Gold Nanoparticles for in vitro and in vivo Gene Silencing ACS Nano 2012, 6, 8316-8324
369. Gibson, J. D.; Khanal, B. P.; Zubarev, E. R. Paclitaxel-Functionalized Gold Nanoparticles J. Am. Chem. Soc. 2007, 129, 11653-11661
370. Min, Y. Z.; Mao, C. Q.; Chen, S. M.; Ma, G. L.; Wang, J.; Liu, Y. Z. Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System Angew. Chem., Int. Ed. 2012, 51, 6742-6747
371. Wang, F.; Wang, Y. C.; Dou, S.; Xiong, M. H.; Sun, T. M.; Wang, J. Doxorubicin-Tethered Responsive Gold Nanoparticles Facilitate Intracellular Drug Delivery for Overcoming Multidrug Resistance in Cancer Cells ACS Nano 2011, 5, 3679-3692
372. Alikhani, M.; Alikhani, Z.; Raptis, M.; Graves, D. T. TNF-Alpha in vivo Stimulates Apoptosis in Fibroblasts through Caspase-8 Activation and Modulates the Expression of Pro-Apoptotic Genes J. Cell Physiol. 2004, 201, 341-348
373. Watanabe, N.; Niitsu, Y.; Umeno, H.; Kuriyama, H.; Neda, H.; Yamauchi, N.; Maeda, M.; Urushizaki, I. Toxic Effect of Tumor Necrosis Factor on Tumor Vasculature in Mice Cancer Res. 1988, 48, 2179-2183
374. Verhoef, C.; de Wilt, J. H.; Grunhagen, D. J.; van Geel, A. N.; ten Hagen, T. L.; Eggermont, A. M. Isolated Limb Perfusion with Melphalan and TNF-Alpha in the Treatment of Extremity Sarcoma Curr. Treat. Options Oncol. 2007, 8, 417-427
375. Goel, R.; Shah, N.; Visaria, R.; Paciotti, G. F.; Bischof, J. C. Biodistribution of TNF-alpha-coated Gold Nanoparticles in an in vivo Model System Nanomedicine (London, U. K.) 2009, 4, 401-410
376. Visaria, R.; Bischof, J. C.; Loren, M.; Williams, B.; Ebbini, E.; Paciotti, G.; Griffin, R. Nanotherapeutics for Enhancing Thermal Therapy of Cancer Int. J. Hyperthermia 2007, 23, 501-510
377. Libutti, S. K.; Paciotti, G. F.; Byrnes, A. A.; Alexander, H. R., Jr.; Gannon, W. E.; Walker, M.; Seidel, G. D.; Yuldasheva, N.; Tamarkin, L. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel Pegylated Colloidal Gold-rh TNF Nanomedicine Clin. Cancer Res. 2010, 16, 6139-6149
378. Field, J. A.; Luna-Velasco, A.; Boitano, S. A.; Shadman, F.; Ratner, B. D.; Barnes, C.; Sierra-Alvarez, R. Cytotoxicity and Physicochemical Properties of Hafnium Oxide Nanoparticles Chemosphere 2011, 84, 1401-1407
379. Maggiorella, L.; Barouch, G.; Devaux, C.; Pottier, A.; Deutsch, E.; Bourhis, J.; Borghi, E.; Levy, L. Nanoscale Radiotherapy with Hafnium Oxide Nanoparticles Future Oncol. 2012, 8, 1167-1181
380. Marill, J.; Anesary, N. M.; Zhang, P.; Vivet, S.; Borghi, E.; Levy, L.; Pottier, A. Hafnium Oxide Nanoparticles: Toward an in vitro Predictive Biological Effect? Radiat. Oncol. 2014, 9, 150
381. Pottier, A.; Borghi, E.; Levy, L. New Use of Metals as Nanosized Radioenhancers Anticancer Res. 2014, 34, 443-453